0001360214 2020-01-01 2020-06-30 0001360214 2020-08-07 0001360214 2020-06-30 0001360214 2019-12-31 0001360214 HROW:SurfacePharmaceuticalsMember 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsMember 2019-12-31 0001360214 HROW:MeltPharmaceuticalsMember 2020-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2019-12-31 0001360214 2020-04-01 2020-06-30 0001360214 2019-04-01 2019-06-30 0001360214 2019-01-01 2019-06-30 0001360214 HROW:ProductSalesNetMember 2020-04-01 2020-06-30 0001360214 HROW:ProductSalesNetMember 2019-04-01 2019-06-30 0001360214 HROW:ProductSalesNetMember 2020-01-01 2020-06-30 0001360214 HROW:ProductSalesNetMember 2019-01-01 2019-06-30 0001360214 HROW:LicenseRevenuesMember 2020-04-01 2020-06-30 0001360214 HROW:LicenseRevenuesMember 2019-04-01 2019-06-30 0001360214 HROW:LicenseRevenuesMember 2020-01-01 2020-06-30 0001360214 HROW:LicenseRevenuesMember 2019-01-01 2019-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-04-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2019-04-01 2019-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-01-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2019-01-01 2019-06-30 0001360214 HROW:SurfacePharmaceuticalsMember 2020-04-01 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsMember 2019-04-01 2019-06-30 0001360214 HROW:SurfacePharmaceuticalsMember 2020-01-01 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsMember 2019-01-01 2019-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2020-04-01 2020-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2019-04-01 2019-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2020-01-01 2020-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2019-01-01 2019-06-30 0001360214 us-gaap:CommonStockMember 2019-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001360214 us-gaap:RetainedEarningsMember 2019-03-31 0001360214 us-gaap:ParentMember 2019-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2019-03-31 0001360214 2019-03-31 0001360214 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001360214 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001360214 us-gaap:ParentMember 2019-04-01 2019-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001360214 us-gaap:CommonStockMember 2019-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001360214 us-gaap:RetainedEarningsMember 2019-06-30 0001360214 us-gaap:ParentMember 2019-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-06-30 0001360214 2019-06-30 0001360214 us-gaap:CommonStockMember 2020-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001360214 us-gaap:RetainedEarningsMember 2020-03-31 0001360214 us-gaap:ParentMember 2020-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-03-31 0001360214 2020-03-31 0001360214 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001360214 us-gaap:ParentMember 2020-04-01 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001360214 us-gaap:CommonStockMember 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-06-30 0001360214 us-gaap:ParentMember 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-06-30 0001360214 us-gaap:CommonStockMember 2018-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001360214 us-gaap:RetainedEarningsMember 2018-12-31 0001360214 us-gaap:ParentMember 2018-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2018-12-31 0001360214 2018-12-31 0001360214 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001360214 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001360214 us-gaap:ParentMember 2019-01-01 2019-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0001360214 us-gaap:CommonStockMember 2019-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001360214 us-gaap:RetainedEarningsMember 2019-12-31 0001360214 us-gaap:ParentMember 2019-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2019-12-31 0001360214 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001360214 us-gaap:ParentMember 2020-01-01 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember HROW:TGVHealthLLCMember 2020-06-30 0001360214 HROW:StowePharmaceuticalsIncMember HROW:TGVHealthLLCMember 2020-06-30 0001360214 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001360214 HROW:StockOptionsMember 2019-01-01 2019-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-04-01 2020-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 us-gaap:SeriesAPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2019-01-01 2019-01-31 0001360214 us-gaap:SeriesAPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2019-01-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-01-01 2019-01-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-04-01 2019-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-01-01 2019-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-04-01 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2019-04-01 2019-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2019-01-01 2019-06-30 0001360214 HROW:AssetPurchaseAgreementMember HROW:MeltPharmaceuticalsIncMember 2018-12-01 2018-12-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2020-06-30 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 srt:MinimumMember HROW:AssetPurchaseAndLicenseAgreementMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 srt:MaximumMember HROW:AssetPurchaseAndLicenseAgreementMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:DrLindstromMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-12-31 0001360214 srt:MinimumMember us-gaap:PatentsMember 2020-01-01 2020-06-30 0001360214 srt:MaximumMember us-gaap:PatentsMember 2020-01-01 2020-06-30 0001360214 us-gaap:PatentsMember 2020-06-30 0001360214 HROW:LicensesMember 2020-01-01 2020-06-30 0001360214 HROW:LicensesMember 2020-06-30 0001360214 us-gaap:TrademarksMember 2020-01-01 2020-06-30 0001360214 us-gaap:TrademarksMember 2020-06-30 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-06-30 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-06-30 0001360214 us-gaap:TradeNamesMember 2020-01-01 2020-06-30 0001360214 us-gaap:TradeNamesMember 2020-06-30 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2020-01-01 2020-06-30 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2020-01-01 2020-06-30 0001360214 HROW:NonCompetitionClauseMember 2020-06-30 0001360214 HROW:StatePharmacyLicensesMember 2020-01-01 2020-06-30 0001360214 HROW:StatePharmacyLicensesMember 2020-06-30 0001360214 us-gaap:PatentsMember 2020-04-01 2020-06-30 0001360214 us-gaap:PatentsMember 2019-04-01 2019-06-30 0001360214 us-gaap:PatentsMember 2020-01-01 2020-06-30 0001360214 us-gaap:PatentsMember 2019-01-01 2019-06-30 0001360214 HROW:LicensesMember 2020-04-01 2020-06-30 0001360214 HROW:LicensesMember 2019-04-01 2019-06-30 0001360214 HROW:LicensesMember 2019-01-01 2019-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-04-01 2020-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2019-04-01 2019-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001360214 us-gaap:TradeNamesMember 2020-04-01 2020-06-30 0001360214 us-gaap:TradeNamesMember 2019-04-01 2019-06-30 0001360214 us-gaap:TradeNamesMember 2019-01-01 2019-06-30 0001360214 HROW:StatePharmacyLicensesMember 2020-04-01 2020-06-30 0001360214 HROW:StatePharmacyLicensesMember 2019-04-01 2019-06-30 0001360214 HROW:StatePharmacyLicensesMember 2019-01-01 2019-06-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-30 2017-07-31 0001360214 srt:MinimumMember HROW:TermLoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember us-gaap:BaseRateMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:SWKAmendmentMember 2020-04-02 0001360214 HROW:BusinessLoanAgreementMember 2020-04-30 0001360214 HROW:BusinessLoanAgreementMember 2020-04-03 2020-04-30 0001360214 HROW:NotesPayableMember 2020-04-01 2020-06-30 0001360214 HROW:NotesPayableMember 2020-01-01 2020-06-30 0001360214 HROW:NotesPayableMember 2019-04-01 2019-06-30 0001360214 HROW:NotesPayableMember 2019-01-01 2019-06-30 0001360214 HROW:SanDiegoMember 2020-06-30 0001360214 HROW:SanDiegoMember 2020-01-01 2020-06-30 0001360214 HROW:IrvineMember 2020-06-30 0001360214 HROW:IrvineMember 2020-01-01 2020-06-30 0001360214 HROW:LedgewoodMember 2020-06-30 0001360214 HROW:LedgewoodMember 2020-01-01 2020-06-30 0001360214 HROW:NashvilleMember 2020-06-30 0001360214 HROW:NashvilleMember 2020-01-01 2020-06-30 0001360214 HROW:NewJerseyMember 2020-03-31 0001360214 HROW:NewJerseyMember 2020-03-31 2020-06-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-05-01 2020-05-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2020-06-30 0001360214 HROW:StockOptionPlanOneMember 2019-12-31 0001360214 HROW:StockOptionPlanOneMember 2020-01-01 2020-06-30 0001360214 HROW:StockOptionPlanOneMember 2020-06-30 0001360214 HROW:StockOptionPlanMember 2020-06-30 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2020-01-01 2020-06-30 0001360214 HROW:BaumPerformanceOptionMember 2015-07-30 2015-07-31 0001360214 srt:MinimumMember HROW:BaumPerformanceOptionMember 2015-07-31 0001360214 srt:MaximumMember HROW:BaumPerformanceOptionMember 2015-07-31 0001360214 HROW:BaumPerformanceOptionMember 2020-06-03 2020-06-04 0001360214 HROW:StockOptionPlanMember 2020-01-01 2020-06-30 0001360214 HROW:OptionsEmployeesMember 2020-01-01 2020-06-30 0001360214 srt:MinimumMember HROW:OptionsEmployeesMember 2020-01-01 2020-06-30 0001360214 srt:MaximumMember HROW:OptionsEmployeesMember 2020-01-01 2020-06-30 0001360214 HROW:RangeOneMember 2020-01-01 2020-06-30 0001360214 HROW:RangeOneMember 2020-06-30 0001360214 HROW:RangeTwoMember 2020-01-01 2020-06-30 0001360214 HROW:RangeTwoMember 2020-06-30 0001360214 HROW:RangeThreeMember 2020-01-01 2020-06-30 0001360214 HROW:RangeThreeMember 2020-06-30 0001360214 HROW:RangeFourMember 2020-01-01 2020-06-30 0001360214 HROW:RangeFourMember 2020-06-30 0001360214 HROW:RangeFiveMember 2020-01-01 2020-06-30 0001360214 HROW:RangeFiveMember 2020-06-30 0001360214 HROW:StockOptionPlanMember 2020-04-01 2020-06-30 0001360214 HROW:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001360214 HROW:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001360214 HROW:RestrictedStockUnitsRSUOneMember 2020-04-01 2020-06-30 0001360214 HROW:RestrictedStockUnitsRSUOneMember 2020-01-01 2020-06-30 0001360214 HROW:NewMemberOfBoardOfDirectorsMember HROW:RestrictedStockUnitsRSUOneMember 2020-01-01 2020-06-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001360214 HROW:UnvestedRSUMember 2020-06-30 0001360214 HROW:UnvestedRSUMember 2020-01-01 2020-06-30 0001360214 HROW:UnvestedRSUMember 2020-04-01 2020-06-30 0001360214 us-gaap:WarrantMember 2019-12-31 0001360214 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001360214 us-gaap:WarrantMember 2020-06-30 0001360214 HROW:LenderWarrantsMember 2020-01-01 2020-06-30 0001360214 HROW:LenderWarrantsMember 2020-06-30 0001360214 HROW:SettlementWarrantsMember 2020-01-01 2020-06-30 0001360214 HROW:SettlementWarrantsMember 2020-06-30 0001360214 HROW:LenderWarrantsOneMember 2020-01-01 2020-06-30 0001360214 HROW:LenderWarrantsOneMember 2020-06-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember HROW:EllePharmaceuticalLLCMember 2020-01-01 2020-06-30 0001360214 us-gaap:RestrictedStockMember HROW:MayfieldPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember 2020-04-01 2020-06-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:ConsultantMember us-gaap:RestrictedStockMember HROW:MayfieldPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2019-04-01 2019-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2019-01-01 2019-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2019-04-01 2019-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2019-01-01 2019-06-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2019-04-01 2019-06-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2019-01-01 2019-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:SecondPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:FinalPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-04-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-01-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-04-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-01-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember 2020-01-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:SalesAndMarketingAgreementsMember 2020-01-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:SalesAndMarketingAgreementsMember 2020-04-01 2020-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-04-01 2020-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-01-01 2020-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-04-01 2019-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-01-01 2019-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-12-31 0001360214 2020-01-01 2020-06-02 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember 2020-04-01 2020-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2019-04-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2019-04-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember 2019-04-01 2019-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2019-04-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2019-01-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2019-01-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember 2019-01-01 2019-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001360214 HROW:ThreeMainSuppliersMember 2020-04-01 2020-06-30 0001360214 HROW:ThreeMainSuppliersMember 2019-04-01 2019-06-30 0001360214 HROW:ThreeMainSuppliersMember 2020-01-01 2020-06-30 0001360214 HROW:ThreeMainSuppliersMember 2019-01-01 2019-06-30 0001360214 us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0001360214 us-gaap:SubsequentEventMember 2020-07-31 0001360214 us-gaap:SubsequentEventMember 2020-08-01 2020-08-02 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001360214 false Q2 2020 Accelerated Filer --12-31 true true 10-Q true 2020-06-30 false 001-35814 Harrow Health, Inc. DE 45-0567010 102 Woodmont Blvd. Suite 610 Nashville TN 37205 (615) 733-4730 Yes Yes true false false Common Stock, $0.001 par value per share HROW NASDAQ 25649671 200000 200000 4102000 4949000 19075000 25200000 2018000 2009000 3841000 3301000 1333000 1308000 30369000 36767000 4993000 5375000 6259000 6559000 1960000 2337000 2809000 3747000 2732000 3968000 332000 332000 49454000 59085000 5780000 7702000 3169000 2117000 53000 57000 827000 2595000 1772000 651000 629000 8000 7000 13083000 12284000 6026000 6338000 22000 26000 800000 800000 1140000 12987000 12219000 34058000 31667000 0.001 0.001 50000000 50000000 25649171 25649171 25526931 25526931 26000 26000 102889000 101728000 -87187000 -74043000 15728000 27711000 -332000 -293000 15396000 27418000 49454000 59085000 8049000 13509000 19859000 25792000 11000 7000 18000 14000 8060000 13516000 19877000 25806000 3204000 5225000 6830000 9123000 4856000 8291000 13047000 16683000 6954000 8248000 15370000 16791000 749000 810000 1152000 1215000 363000 363000 8066000 9058000 16885000 18006000 -3210000 -767000 -3838000 -1323000 -505000 -716000 -1065000 -1319000 -690000 -326000 -1236000 5199000 -599000 -261000 -938000 -504000 4725000 -350000 -6125000 6230000 19000 19000 630000 2950000 -1653000 -9345000 10236000 -260000 -2420000 -13183000 8913000 -260000 -2420000 -13183000 8913000 23000 42000 39000 67000 -237000 -2378000 -13144000 8980000 -0.01 -0.09 -0.51 0.36 -0.01 -0.09 -0.51 0.34 25893629 25216565 25867478 25030012 25893629 25216565 25867478 26696683 24718649 25000 99887000 -62853000 37059000 -25000 37034000 399354 17000 17000 17000 20955 367000 367000 367000 -2378000 -2378000 -42000 -2420000 25138958 25000 100271000 -65231000 35065000 -67000 34998000 25618918 26000 102261000 -86950000 15337000 -309000 15028000 253 30000 83000 83000 83000 545000 545000 545000 -237000 -237000 -23000 -260000 25649171 26000 102889000 -87187000 15728000 -332000 15396000 24339610 24000 98938000 -74211000 24751000 24751000 763393 1000 178000 179000 179000 20955 15000 75000 75000 75000 1080000 1080000 1080000 8980000 8980000 -67000 8913000 25138958 25000 100271000 -65231000 35065000 -67000 34998000 25526931 26000 101728000 -74043000 27711000 -293000 27418000 253 91987 30000 83000 83000 83000 1078000 1078000 1078000 -13144000 -13144000 -39000 -13183000 25649171 26000 102889000 -87187000 15728000 -332000 15396000 -13183000 8913000 913000 968000 88000 125000 341000 256000 243000 263000 302000 -6125000 6230000 -938000 -504000 -1236000 5199000 -5000 -76000 348000 363000 83000 75000 1078000 1080000 311000 309000 540000 818000 25000 564000 -2253000 830000 1052000 -707000 -4000 105000 -3201000 -632000 74000 220000 536000 565000 -610000 -785000 3000 375000 1000000 750000 282000 1967000 179000 2964000 -1228000 -847000 -2645000 4949000 6838000 4102000 4193000 3902000 3993000 200000 200000 4102000 4193000 8000 408000 1053000 41000 40000 11000 <p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zlPzhX7ymvD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1. <span id="xdx_822_zdcr74i0kJHf">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Company and Background</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) specializes in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns one of the nation’s leading ophthalmology-focused pharmaceutical businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (“Eton”), Surface Pharmaceuticals, Inc. (“Surface”), and Melt Pharmaceuticals, Inc. (“Melt”), all companies that began as subsidiaries of Harrow. More recently, the Company founded drug development subsidiaries Mayfield Pharmaceuticals, Inc. (“Mayfield”) and Stowe Pharmaceuticals, Inc. (“Stowe”), among others. In 2020, Harrow created Visionology, Inc., which intends to launch an online eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface, Melt and Mayfield. The Company intends to continue to create, and hold equity and royalty rights in, new businesses that commercialize drug candidates that are internally developed or otherwise acquired or licensed from third parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, as well as Mayfield <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zHnXJig7VGA6">(</span></span><span style="font: 10pt Times New Roman, Times, Serif">79% majority controlled) and Stowe <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_znlfDUfuPR14">(</span></span><span style="font: 10pt Times New Roman, Times, Serif">70% majority controlled) each subsidiaries of Harrow as of June 30, 2020. The remaining <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zkpBcyBgVMgh">21</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of Mayfield is owned by Elle Pharmaceutical, LLC (“Elle”), TGV-Health, LLC and its affiliated entities (collectively “TGV”) or other consultants. Mayfield was organized to develop women’s health-focused drug candidates. The remaining <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_ziHW5CIxYtB8">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of Stowe is owned by TGV. Stowe was organized to develop ophthalmic drug candidates. All inter-company accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow consolidates entities in which it has a controlling financial interest. <span id="xdx_90E_ecustom--ConsolidationBasisDescription_c20200101__20200630" title="Consolidation basis, description">We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights.</span> All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated balance sheets at June 30, 2020 and December 31, 2019 and the condensed consolidated statements of operations, stockholders’ equity and cash flows for the periods ended June 30, 2020 and 2019 include our accounts and those of our wholly owned subsidiaries as well as Mayfield and Stowe.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks, Uncertainties and Liquidity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare &amp; Medicaid Services (“CMS”) released guidance for U.S. healthcare providers to limit all elective medical procedures in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant volatility in financial markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Many of the Company’s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition, the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other activities required to achieve regulatory clearance of products under development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company believes reductions in elective procedures in response to CMS guidance have had, and will continue to have, an adverse impact, which may be material, on the Company’s financial condition, liquidity and results of operations. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and cannot be predicted. As of the date of issuance of this Quarterly Report, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. For further information, refer to “Risk Factors” in Part II, Item 1A of this Quarterly Report and information in the Company’s other filings with the Securities and Exchange Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has incurred significant operating losses and negative cash flows from operations since its inception. The Company incurred operating losses of $<span id="xdx_905_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20200101__20200630_zGbj7i6Iaura">3,838</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20190101__20190630_zbcfSQHHczO8">1,323 </span></span><span style="font: 10pt Times New Roman, Times, Serif">for the six months ended June 30, 2020 and 2019, respectively, and had an accumulated deficit of $<span id="xdx_909_ecustom--RetainedEarningsAccumulatedDeficit1_iNI_pn3n3_di_c20200630_zp3HWnMh72L1">87,187 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_ecustom--RetainedEarningsAccumulatedDeficit1_iNI_pn3n3_di_c20191231_zDMKqRxX4vWf">74,043 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as of June 30, 2020 and December 31, 2019, respectively. In addition, the Company used cash in operating activities of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20200101__20200630_z4CYSWotALme">3,201 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20190101__20190630_zBh0uEWOrD5k">632 </span></span><span style="font: 10pt Times New Roman, Times, Serif">for the six months ended June 30, 2020 and 2019, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">While there is no assurance, management of the Company believes existing cash resources and restricted cash of $<span id="xdx_90A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20200630_pn3n3">4,102 </span></span><span style="font: 10pt Times New Roman, Times, Serif">at June 30, 2020 together with cash generated from revenues, will be sufficient to sustain the Company’s planned level of operations for at least the next twelve months. However, estimates of operating expenses and working capital requirements could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited to: the sale of assets, investments and/or businesses, obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain capital when needed on terms management deems acceptable, or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 0.21 0.30 We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights. -3838000 -1323000 -87187000 -74043000 -3201000 -632000 4102000 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zf1vXEPWbZOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2. <span id="xdx_821_zOE4CWXDpFE1">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following represents an update for the three and six months ended June 30, 2020 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zbH6B5U330j1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_862_z2jjlMojRzEl">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented as operating segments. The Company has identified two operating segments as reportable segments. See Note 15 for more information regarding the Company’s reportable segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zBN6XfKUqdqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86B_zRpplf7Pv5Dg">Noncontrolling Interests</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly owned subsidiary not attributable to the Company. <span id="xdx_903_eus-gaap--MinorityInterestDescription_c20200101__20200630" title="Non-controlling interest description">Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well.</span> The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">net income or loss;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each component of other income or loss.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zule2Dk7oI8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_868_znrWBqTlmMvb">Basic and Diluted Net Income (Loss) per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested restricted stock units (“RSUs”) and warrants were <span id="xdx_90C_ecustom--UnvestedRestrictedStockUnits_c20200101__20200630_pii" title="Unvested restricted stock units">5,414,504</span> and <span id="xdx_90D_ecustom--UnvestedRestrictedStockUnits_c20190101__20190630_pii" title="Unvested restricted stock units">5,331,883</span> at June 30, 2020 and 2019, respectively, and, except for the six months ended June 30, 2019, are excluded from the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at June 30, 2020 and 2019 was <span id="xdx_906_ecustom--VestedRestrictedStockUnits_c20200101__20200630_pii" title="Vested restricted stock units">251,746</span> and <span id="xdx_907_ecustom--VestedRestrictedStockUnits_c20190101__20190630_pii" title="Vested restricted stock units">304,873</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zGMMiWMojBMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table shows the computation of basic net income (loss) per share of common stock for the three and six months ended June 30, 2020 and 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_8BE_zSIZqMt4XdYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE OF BASIC EARNINGS PER COMMON SHARE </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200401__20200630_zBPs5qM8nbei" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20190401__20190630_zuBnxrgVe7Ai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20200101__20200630_zizNupSD0Jo2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20190101__20190630_zAPxUbvitjZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--NetIncomeLoss1_z7zbtX74sYB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(13,144</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,980</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zDnOuHbG1Lg4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,216,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,030,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pii_zZJP5xUhzJU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zfqm0ZuYeNA" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zKXGilEaEvB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the six months ended June 30, 2019, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the six months ended June 30, 2019, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B0_zYKiWYv3Vge7" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the</p> <p style="margin-top: 0; margin-bottom: 0">Six Months Ended</p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 72%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zEoJJZleocJ2" style="width: 24%; text-align: right">1,028,780</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zzZASZPVOv1a" style="border-bottom: Black 1.5pt solid; text-align: right">637,891</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630_z4a2ID73rK04" style="border-bottom: Black 2.5pt double; text-align: right">1,666,671</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zlpS6641KQNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_z2mc4ezS3jNi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The following table shows the computation of diluted net income (loss) per share of common stock for the three and six months ended June 30, 2020 and 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zgrSbMfGB0Yj" style="display: none">SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200401__20200630_z3SzfRiIpZXh" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20190401__20190630_zclBjBC2Jwlj" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200101__20200630_z00tu0PrlDk7" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20190101__20190630_zeNXMBzwx4B5" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_zkyBqzV6fbz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(13,144</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,980</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zATbjuo7azWk" style="vertical-align: bottom; background-color: White"> <td>Denominator – weighted average number of shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,893,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,216,565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,867,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,030,012</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zi4b9v7yxxJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0794"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0795"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0796"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,666,671</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zbEVgKKP3rXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted income (loss) per share computation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,216,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,696,683</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pii_z4eiQ16t6ms5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_8A6_zFCatdLkn4Sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_z7mEkCQchIRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/><span><b><span id="xdx_86D_zfGIxzllrDn7">Investment in Eton Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company owns <span id="xdx_906_ecustom--NumberOfSharesOwned_iI_pii_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z6dKkQ1D8Bb">3,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Eton common stock, which represents approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zneqaUemGITh">16.7</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the equity and voting interests of Eton as of June 30, 2020. At June 30, 2020 the fair market value of Eton’s common stock was $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii">5.45 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>, for the three and six months ended June 30, 2020, the Company recorded an investment gain (loss) from its Eton common stock position of $<span id="xdx_90B_eus-gaap--GainLossOnInvestments_c20200401__20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">4,725 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--GainLossOnInvestments_c20200101__20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">(6,125), respectively</span></span><span style="font: 10pt Times New Roman, Times, Serif">, related to the change in fair market value of the Company’s investment in Eton during the measurement periods. As of June 30, 2020, the fair market value of the Company’s investment in Eton was $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">19,075</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mark Baum, the Company’s Chief Executive Officer, is a member of the board of directors of Eton.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_ecustom--InvestmentOnePolicyTextBlock_z7faXTAAEq2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_869_zweQrGlMtl22">Investment in Melt Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In April 2018, the Company formed Melt as a wholly owned subsidiary. In January and March of 2019, Melt entered into definitive stock purchase agreements (collectively, the “Melt Series A Preferred Stock Agreement”) with certain investors and closed on the sale of Melt’s Series A Preferred Stock (the “Melt Series A Stock”), totaling approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3">11,400 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of proceeds (collectively the “Melt Series A Round”) at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_c20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii">5.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. As a result, the Company lost voting and ownership control of Melt and ceased consolidating Melt’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2019, the Company deconsolidated Melt and recorded a gain of $<span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Gain on deconsolidation amount">5,810</span> and adjusted the carrying value in Melt to reflect the increased valuation of Melt and the Company’s new ownership interest in accordance with Accounting Standard Codification (“ASC”) 810-10-40-4(c), <i>Consolidation</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company owns <span id="xdx_900_ecustom--NumberOfSharesOwned_iI_pii_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjUpxACrTi86">3,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares of Melt (which is approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOBpV5loaS0b">44</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the equity interests as of June 30, 2020) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Melt of $690 and $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">1,236 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2020, respectively. The Company recorded equity in the net loss of Melt of $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnInvestments_c20190401__20190630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">326 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20190630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">611 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2019, respectively. As of June 30, 2020, the carrying value of the Company’s investment in Melt was $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">2,732</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See Note 4 for more information and related party disclosure regarding Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_ecustom--InvestmentTwoPolicyTextBlock_zwOVIiUA5Ci5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zjMfnRLfM304">Investment in Surface Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company owns <span id="xdx_90E_ecustom--NumberOfSharesOwned_iI_pii_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zxugESdZJ7f4">3,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares (which is approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zfjH6okE8T46">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the equity interests as of June 30, 2020) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Surface of $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20200401__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">599 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">938 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2020, respectively. The Company recorded equity in the net loss of Surface of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20190401__20190630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">261 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20190630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">504 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2019, respectively. As of June 30, 2020, the carrying value of the Company’s investment in Surface was $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">2,809</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See Note 5 for more information and related party disclosure regarding Surface.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_84E_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zkGOnESqHDIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86E_zlAYXwD5kQ22">Recently Adopted Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In August 2018, the FASB issued ASU 2018-13, <i>Changes to Disclosure Requirements for Fair Value Measurements</i>, which improved the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2017, the FASB issued ASU 2017-04, <i>Intangibles-Goodwill and Other</i>. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for reporting periods beginning after December 31, 2019 on a prospective basis, and early adoption is permitted. The Company adopted ASU 2017-04 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv1UQZgZXX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_861_zJQGxaYxmP7">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In December 2019, the FASB issued ASU 2019-12, <i>Simplifying the Accounting for Income Taxes</i>, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted. The Company does not expect ASU 2019-12 to have a material impact on its consolidated financial position, results of operations and cash flows.</span></p> <p id="xdx_857_zmtoY1e9HZHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zbH6B5U330j1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_862_z2jjlMojRzEl">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented as operating segments. The Company has identified two operating segments as reportable segments. See Note 15 for more information regarding the Company’s reportable segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zBN6XfKUqdqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86B_zRpplf7Pv5Dg">Noncontrolling Interests</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly owned subsidiary not attributable to the Company. <span id="xdx_903_eus-gaap--MinorityInterestDescription_c20200101__20200630" title="Non-controlling interest description">Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well.</span> The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">net income or loss;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each component of other income or loss.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zule2Dk7oI8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_868_znrWBqTlmMvb">Basic and Diluted Net Income (Loss) per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested restricted stock units (“RSUs”) and warrants were <span id="xdx_90C_ecustom--UnvestedRestrictedStockUnits_c20200101__20200630_pii" title="Unvested restricted stock units">5,414,504</span> and <span id="xdx_90D_ecustom--UnvestedRestrictedStockUnits_c20190101__20190630_pii" title="Unvested restricted stock units">5,331,883</span> at June 30, 2020 and 2019, respectively, and, except for the six months ended June 30, 2019, are excluded from the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at June 30, 2020 and 2019 was <span id="xdx_906_ecustom--VestedRestrictedStockUnits_c20200101__20200630_pii" title="Vested restricted stock units">251,746</span> and <span id="xdx_907_ecustom--VestedRestrictedStockUnits_c20190101__20190630_pii" title="Vested restricted stock units">304,873</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zGMMiWMojBMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table shows the computation of basic net income (loss) per share of common stock for the three and six months ended June 30, 2020 and 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_8BE_zSIZqMt4XdYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE OF BASIC EARNINGS PER COMMON SHARE </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200401__20200630_zBPs5qM8nbei" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20190401__20190630_zuBnxrgVe7Ai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20200101__20200630_zizNupSD0Jo2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20190101__20190630_zAPxUbvitjZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--NetIncomeLoss1_z7zbtX74sYB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(13,144</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,980</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zDnOuHbG1Lg4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,216,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,030,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pii_zZJP5xUhzJU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zfqm0ZuYeNA" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zKXGilEaEvB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the six months ended June 30, 2019, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the six months ended June 30, 2019, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B0_zYKiWYv3Vge7" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the</p> <p style="margin-top: 0; margin-bottom: 0">Six Months Ended</p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 72%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zEoJJZleocJ2" style="width: 24%; text-align: right">1,028,780</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zzZASZPVOv1a" style="border-bottom: Black 1.5pt solid; text-align: right">637,891</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630_z4a2ID73rK04" style="border-bottom: Black 2.5pt double; text-align: right">1,666,671</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zlpS6641KQNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_z2mc4ezS3jNi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The following table shows the computation of diluted net income (loss) per share of common stock for the three and six months ended June 30, 2020 and 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zgrSbMfGB0Yj" style="display: none">SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200401__20200630_z3SzfRiIpZXh" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20190401__20190630_zclBjBC2Jwlj" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200101__20200630_z00tu0PrlDk7" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20190101__20190630_zeNXMBzwx4B5" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_zkyBqzV6fbz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(13,144</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,980</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zATbjuo7azWk" style="vertical-align: bottom; background-color: White"> <td>Denominator – weighted average number of shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,893,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,216,565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,867,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,030,012</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zi4b9v7yxxJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0794"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0795"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0796"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,666,671</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zbEVgKKP3rXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted income (loss) per share computation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,216,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,696,683</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pii_z4eiQ16t6ms5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_8A6_zFCatdLkn4Sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> 5414504 5331883 251746 304873 <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zGMMiWMojBMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table shows the computation of basic net income (loss) per share of common stock for the three and six months ended June 30, 2020 and 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_8BE_zSIZqMt4XdYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE OF BASIC EARNINGS PER COMMON SHARE </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200401__20200630_zBPs5qM8nbei" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20190401__20190630_zuBnxrgVe7Ai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20200101__20200630_zizNupSD0Jo2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20190101__20190630_zAPxUbvitjZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--NetIncomeLoss1_z7zbtX74sYB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(13,144</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,980</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zDnOuHbG1Lg4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,216,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,030,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pii_zZJP5xUhzJU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -237000 -2378000 -13144000 8980000 25893629 25216565 25867478 25030012 -0.01 -0.09 -0.51 0.36 <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zKXGilEaEvB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the six months ended June 30, 2019, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the six months ended June 30, 2019, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B0_zYKiWYv3Vge7" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the</p> <p style="margin-top: 0; margin-bottom: 0">Six Months Ended</p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 72%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zEoJJZleocJ2" style="width: 24%; text-align: right">1,028,780</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zzZASZPVOv1a" style="border-bottom: Black 1.5pt solid; text-align: right">637,891</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20190101__20190630_z4a2ID73rK04" style="border-bottom: Black 2.5pt double; text-align: right">1,666,671</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1028780 637891 1666671 <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_z2mc4ezS3jNi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The following table shows the computation of diluted net income (loss) per share of common stock for the three and six months ended June 30, 2020 and 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zgrSbMfGB0Yj" style="display: none">SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200401__20200630_z3SzfRiIpZXh" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20190401__20190630_zclBjBC2Jwlj" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200101__20200630_z00tu0PrlDk7" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20190101__20190630_zeNXMBzwx4B5" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_zkyBqzV6fbz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(13,144</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,980</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zATbjuo7azWk" style="vertical-align: bottom; background-color: White"> <td>Denominator – weighted average number of shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,893,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,216,565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,867,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,030,012</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zi4b9v7yxxJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0794"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0795"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0796"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,666,671</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zbEVgKKP3rXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted income (loss) per share computation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,216,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,696,683</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pii_z4eiQ16t6ms5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> -237000 -2378000 -13144000 8980000 25893629 25216565 25867478 25030012 1666671 25893629 25216565 25867478 26696683 -0.01 -0.09 -0.51 0.34 <p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_z7mEkCQchIRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/><span><b><span id="xdx_86D_zfGIxzllrDn7">Investment in Eton Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company owns <span id="xdx_906_ecustom--NumberOfSharesOwned_iI_pii_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z6dKkQ1D8Bb">3,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Eton common stock, which represents approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zneqaUemGITh">16.7</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the equity and voting interests of Eton as of June 30, 2020. At June 30, 2020 the fair market value of Eton’s common stock was $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii">5.45 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>, for the three and six months ended June 30, 2020, the Company recorded an investment gain (loss) from its Eton common stock position of $<span id="xdx_90B_eus-gaap--GainLossOnInvestments_c20200401__20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">4,725 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--GainLossOnInvestments_c20200101__20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">(6,125), respectively</span></span><span style="font: 10pt Times New Roman, Times, Serif">, related to the change in fair market value of the Company’s investment in Eton during the measurement periods. As of June 30, 2020, the fair market value of the Company’s investment in Eton was $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_c20200630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">19,075</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mark Baum, the Company’s Chief Executive Officer, is a member of the board of directors of Eton.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 3500000 0.167 5.45 4725000 -6125000 19075000 <p id="xdx_846_ecustom--InvestmentOnePolicyTextBlock_z7faXTAAEq2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_869_zweQrGlMtl22">Investment in Melt Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In April 2018, the Company formed Melt as a wholly owned subsidiary. In January and March of 2019, Melt entered into definitive stock purchase agreements (collectively, the “Melt Series A Preferred Stock Agreement”) with certain investors and closed on the sale of Melt’s Series A Preferred Stock (the “Melt Series A Stock”), totaling approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3">11,400 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of proceeds (collectively the “Melt Series A Round”) at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_c20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii">5.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. As a result, the Company lost voting and ownership control of Melt and ceased consolidating Melt’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2019, the Company deconsolidated Melt and recorded a gain of $<span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Gain on deconsolidation amount">5,810</span> and adjusted the carrying value in Melt to reflect the increased valuation of Melt and the Company’s new ownership interest in accordance with Accounting Standard Codification (“ASC”) 810-10-40-4(c), <i>Consolidation</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company owns <span id="xdx_900_ecustom--NumberOfSharesOwned_iI_pii_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjUpxACrTi86">3,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares of Melt (which is approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOBpV5loaS0b">44</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the equity interests as of June 30, 2020) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Melt of $690 and $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">1,236 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2020, respectively. The Company recorded equity in the net loss of Melt of $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnInvestments_c20190401__20190630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">326 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20190630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">611 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2019, respectively. As of June 30, 2020, the carrying value of the Company’s investment in Melt was $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">2,732</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See Note 4 for more information and related party disclosure regarding Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 11400000 5.00 5810000 3500000 0.44 1236000 326000 611000 2732000 <p id="xdx_846_ecustom--InvestmentTwoPolicyTextBlock_zwOVIiUA5Ci5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zjMfnRLfM304">Investment in Surface Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company owns <span id="xdx_90E_ecustom--NumberOfSharesOwned_iI_pii_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zxugESdZJ7f4">3,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares (which is approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zfjH6okE8T46">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the equity interests as of June 30, 2020) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Surface of $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20200401__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">599 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">938 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2020, respectively. The Company recorded equity in the net loss of Surface of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20190401__20190630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">261 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20190630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">504 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2019, respectively. As of June 30, 2020, the carrying value of the Company’s investment in Surface was $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">2,809</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See Note 5 for more information and related party disclosure regarding Surface.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 3500000 0.30 599000 938000 261000 504000 2809000 <p id="xdx_84E_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zkGOnESqHDIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86E_zlAYXwD5kQ22">Recently Adopted Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In August 2018, the FASB issued ASU 2018-13, <i>Changes to Disclosure Requirements for Fair Value Measurements</i>, which improved the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2017, the FASB issued ASU 2017-04, <i>Intangibles-Goodwill and Other</i>. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for reporting periods beginning after December 31, 2019 on a prospective basis, and early adoption is permitted. The Company adopted ASU 2017-04 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv1UQZgZXX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_861_zJQGxaYxmP7">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In December 2019, the FASB issued ASU 2019-12, <i>Simplifying the Accounting for Income Taxes</i>, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted. The Company does not expect ASU 2019-12 to have a material impact on its consolidated financial position, results of operations and cash flows.</span></p> <p id="xdx_803_eus-gaap--RevenueFromContractWithCustomerTextBlock_zgguodIlzHV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3. <span id="xdx_82F_zl9W0jXwzbc4">REVENUES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for contracts with customers in accordance with ASC 606, <i>Revenues from Contracts with Customers</i>. The Company has two primary streams of revenues: (1) revenues recognized from our sale of products within our pharmacy services and (2) revenues recognized from intellectual property license and asset purchase agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Product Revenues from Pharmacy Services</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenues from our pharmacy services division includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principle of ASC 606, we have identified the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation, the customer is notified.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price: the transaction price is based on the product being sold to the customer, and any related customer discounts. These amounts are pre-determined and built into our order management software.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being ordered is allocated according to the pre-determined amounts.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility, the performance obligation has been met.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following revenue recognition policy has been established for the pharmacy services division:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenues generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Intellectual Property License Revenues</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently holds five intellectual property license and related agreements in which the Company has sold or granted a license which provides a customer with the right to access the Company’s intellectual property. License arrangements may include or require non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point of time the performance obligation is met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwZR9JtI1SB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenue disaggregated by revenue source for the three and six months ended June 30, 2020 and 2019, consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zavabmzyTlDb" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE OF DISAGGREGATED REVENUE</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">Product sales, net</span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z3rumq00QgFi" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">8,049</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zzQ4bfHHeWea" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">13,509</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z1orN6Lu5Hl1" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">19,859</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zT1h829hg7Tb" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">25,792</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">License</span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zZvsaao0jtr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_z3fwudk0jB4a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zRyXUgJCEdAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">18</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zK6MBwnXpeUi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-weight: bold; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">Total revenues</span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630_zrrkp5sizpv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">8,060</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_zJNQUFqYPSf8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">13,516</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630_zaYoAL2ZjGBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">19,877</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630_zMf9wJ3AU0bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">25,806</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred revenue and customer deposits at June 30, 2020 and December 31, 2019, was $<span id="xdx_907_eus-gaap--ContractWithCustomerLiabilityCurrent_c20200630_pn3n3" title="Deferred revenue and customer deposits">53</span> and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_c20191231_pn3n3" title="Deferred revenue and customer deposits">57</span>, respectively. All deferred revenue and customer deposit amounts at December 31, 2019 were recognized as revenue during the six months ended June 30, 2020.</span></p> <p id="xdx_8AC_z5i9KfC25j03" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwZR9JtI1SB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenue disaggregated by revenue source for the three and six months ended June 30, 2020 and 2019, consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zavabmzyTlDb" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE OF DISAGGREGATED REVENUE</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">Product sales, net</span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z3rumq00QgFi" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">8,049</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zzQ4bfHHeWea" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">13,509</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z1orN6Lu5Hl1" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">19,859</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zT1h829hg7Tb" style="width: 12%; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">25,792</span></td><td style="width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">License</span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zZvsaao0jtr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_z3fwudk0jB4a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zRyXUgJCEdAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">18</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zK6MBwnXpeUi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-weight: bold; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">Total revenues</span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630_zrrkp5sizpv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">8,060</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_zJNQUFqYPSf8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">13,516</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630_zaYoAL2ZjGBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">19,877</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630_zMf9wJ3AU0bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues"><span style="font: normal 10pt Times New Roman, Times, Serif">25,806</span></td><td style="text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred revenue and customer deposits at June 30, 2020 and December 31, 2019, was $<span id="xdx_907_eus-gaap--ContractWithCustomerLiabilityCurrent_c20200630_pn3n3" title="Deferred revenue and customer deposits">53</span> and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_c20191231_pn3n3" title="Deferred revenue and customer deposits">57</span>, respectively. All deferred revenue and customer deposit amounts at December 31, 2019 were recognized as revenue during the six months ended June 30, 2020.</span></p> 8049000 13509000 19859000 25792000 11000 7000 18000 14000 8060000 13516000 19877000 25806000 53000 57000 <p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zyHoynsbSx6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4. <span id="xdx_82C_zJYpjZjm4kwi">INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make royalty payments to the Company up to <span id="xdx_906_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_c20181201__20181231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z7WcXedgbkle" title="Royalty payment percentage on net sales">5</span>% of net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In February 2019, the Company and Melt entered into a Management Services Agreement (the “Melt MSA”), whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt pays the Company a monthly amount of $<span id="xdx_90F_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3" title="Administrative expenses">10</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2020, the Company was due $<span id="xdx_908_eus-gaap--DueFromRelatedParties_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3" title="Reimbursable expenses due">785</span> from Melt for reimbursable expenses and amounts due under the Melt MSA and are included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. During the three and six months ended June 30, 2020, Melt paid the Company $<span id="xdx_900_eus-gaap--ProceedsFromRelatedPartyDebt_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3" title="Proceeds from related party payments">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, are members of the Melt board of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zFZuV573WnB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed results of operations information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BC_z76ASQQPgg8g" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Revenues, net"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 28%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Loss from operations">2,574</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A0_zUxEacGaM69h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_894_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zS1t7D1yUqHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed balance sheet information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zknTz6pTgTZ4" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsCurrent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">4,789</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AssetsNoncurrent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">4,801</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Liabilities_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,495</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total preferred stock and stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockholdersEquity_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity">3,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesAndStockholdersEquity_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">4,801</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zzQMgepjRui4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0.05 10000 785000 0 <p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zFZuV573WnB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed results of operations information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BC_z76ASQQPgg8g" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Revenues, net"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 28%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Loss from operations">2,574</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 2574000 -2574000 <p id="xdx_894_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zS1t7D1yUqHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed balance sheet information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zknTz6pTgTZ4" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsCurrent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">4,789</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AssetsNoncurrent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">4,801</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Liabilities_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,495</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total preferred stock and stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockholdersEquity_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity">3,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesAndStockholdersEquity_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">4,801</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4789000 12000 4801000 1495000 3306000 4801000 <p id="xdx_80E_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_zvcG9zfE9154" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5. <span id="xdx_825_zklNgI36Jpp7">INVESTMENT IN SURFACE PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company entered into an asset purchase and license agreement with Surface in 2017, and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights to develop, formulate, make, sell, and sub-license ophthalmic formulations (collectively, the “Surface Products”). Surface is required to make royalty payments to the Company of <span id="xdx_904_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAndLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zlBo75FQPZC2">4</span></span><span style="font: 10pt Times New Roman, Times, Serif">%-<span id="xdx_90E_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAndLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zBmdc7jXESBe">6</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of net sales of the Surface Products while any patent rights remain outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A Company director, Richard L. Lindstrom, and the Company’s Chief Executive Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of <span id="xdx_902_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--DrLindstromMember_zmNcOKrNJFRb">3</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of net sales of certain Surface Products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_892_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zmNXejTz6Wj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed results of operations information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_z1zPf7H1BcCh" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY OF CONDENSED INCOME STATEMENT </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z50JblSu1ynj" style="border-bottom: Black 1.5pt solid; width: 28%; text-align: right" title="Loss from operations">3,127</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(3,127</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AC_zMRcHgpstxCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zEFKWJ6tgZ9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed balance sheet information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BF_zGP0jrXoxn8b" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY OF CONDENSED BALANCE SHEET </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsCurrent_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">12,911</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsNoncurrent_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">12,956</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Liabilities_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">642</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockholdersEquity_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">12,314</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesAndStockholdersEquity_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">12,956</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zhTG6fJmyCn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 0.04 0.06 0.03 <p id="xdx_892_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zmNXejTz6Wj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed results of operations information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_z1zPf7H1BcCh" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY OF CONDENSED INCOME STATEMENT </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">For the</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Six Months Ended</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z50JblSu1ynj" style="border-bottom: Black 1.5pt solid; width: 28%; text-align: right" title="Loss from operations">3,127</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(3,127</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 3127000 -3127000 <p id="xdx_89A_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zEFKWJ6tgZ9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed balance sheet information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BF_zGP0jrXoxn8b" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY OF CONDENSED BALANCE SHEET </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsCurrent_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">12,911</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsNoncurrent_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">12,956</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Liabilities_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">642</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockholdersEquity_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">12,314</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesAndStockholdersEquity_c20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">12,956</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 12911000 45000 12956000 642000 12314000 12956000 <p id="xdx_805_eus-gaap--InventoryDisclosureTextBlock_zkOPFme1n5Fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6.<span id="xdx_828_zIm1WrqjS672"> INVENTORIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zNHOOyEXF6Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of June 30, 2020 and December 31, 2019 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_z7EUQI4LsKZe" style="display: none">SCHEDULE OF INVENTORIES</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200630_zgYwnUe5YKu5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20191231_zdRFvsoQgRji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzZOs_z9EncFF5Wmne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,758</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,405</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzZOs_zU5axfl2ukG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzZOs_zIgtB3KjT5L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,081</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">876</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iTI_pn3n3_mtINzZOs_z9DJvj73OiCc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,841</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,301</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zHZ3VrNidlna" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zNHOOyEXF6Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of June 30, 2020 and December 31, 2019 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_z7EUQI4LsKZe" style="display: none">SCHEDULE OF INVENTORIES</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200630_zgYwnUe5YKu5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20191231_zdRFvsoQgRji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzZOs_z9EncFF5Wmne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,758</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,405</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzZOs_zU5axfl2ukG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzZOs_zIgtB3KjT5L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,081</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">876</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iTI_pn3n3_mtINzZOs_z9DJvj73OiCc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,841</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,301</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2758000 2405000 2000 20000 1081000 876000 3841000 3301000 <p id="xdx_803_eus-gaap--OtherAssetsDisclosureTextBlock_zoWK9pfAkvdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7. <span id="xdx_822_zuoINoh1j5Z7">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zBaQtK0HEFrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_z8G258i2oMml" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--PrepaidInsurance_c20200630_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">98</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PrepaidInsurance_c20191231_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">123</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OtherPrepaidExpenseCurrent_c20200630_pn3n3" style="text-align: right" title="Other prepaid expenses">361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OtherPrepaidExpenseCurrent_c20191231_pn3n3" style="text-align: right" title="Other prepaid expenses">358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DueFromRelatedPartiesCurrent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DueFromRelatedPartiesCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">722</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OtherAssetsCurrent_c20200630_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherAssetsCurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iI_pn3n3_c20200630_zcuBlXBwHT3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iI_pn3n3_c20191231_z3b011keu5E" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,308</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zz0TSWqsci2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zBaQtK0HEFrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_z8G258i2oMml" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--PrepaidInsurance_c20200630_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">98</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PrepaidInsurance_c20191231_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">123</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OtherPrepaidExpenseCurrent_c20200630_pn3n3" style="text-align: right" title="Other prepaid expenses">361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OtherPrepaidExpenseCurrent_c20191231_pn3n3" style="text-align: right" title="Other prepaid expenses">358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DueFromRelatedPartiesCurrent_c20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DueFromRelatedPartiesCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">722</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OtherAssetsCurrent_c20200630_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherAssetsCurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iI_pn3n3_c20200630_zcuBlXBwHT3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iI_pn3n3_c20191231_z3b011keu5E" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,308</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 98000 123000 361000 358000 785000 722000 89000 105000 1333000 1308000 <p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zCPKb87xZKda" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8. <span id="xdx_82E_zzah2d9Xjt7i">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5e4kwvH2as9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property, plant and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_zvGYDsWokKY9" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20200630_z2itkzAsvCDh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20191231_z70jwQlBkq0e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzOvw_zJf71d41xD4l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Computer software and hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,760</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,732</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzOvw_z62G6ewNdtMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzOvw_zXNN6TeYgo6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,164</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzOvw_zx6viu8uXn3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,674</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzOvw_maPPAENz9zC_z6ClvyLSUWa4" style="vertical-align: bottom; background-color: White"> <td style="visibility: hidden">Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,296</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,769</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9zC_zbu2qgaRusv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,303</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9zC_zVkzAf5lk2ll" style="vertical-align: bottom; background-color: White"> <td style="visibility: hidden; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,993</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zXmKnAA1Mzt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">For the three and six months ended June 30, 2020, depreciation and amortization related to the property, plant and equipment was $<span id="xdx_90F_eus-gaap--DepreciationAmortizationAndAccretionNet_pn3n3_c20200401__20200630_zqBH1dRfEucd">465 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_908_eus-gaap--DepreciationAmortizationAndAccretionNet_pn3n3_c20200101__20200630_zcfmTZ0V5mZk">913</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively. For the three and six months ended June 30, 2019, depreciation and amortization related to the property, plant and equipment was $<span id="xdx_900_eus-gaap--DepreciationAmortizationAndAccretionNet_pn3n3_c20190401__20190630_zuaKeeODlqv8">491 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--DepreciationAmortizationAndAccretionNet_pn3n3_c20190101__20190630_zSux2MGqB2n4">968</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5e4kwvH2as9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property, plant and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_zvGYDsWokKY9" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20200630_z2itkzAsvCDh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20191231_z70jwQlBkq0e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzOvw_zJf71d41xD4l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Computer software and hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,760</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,732</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzOvw_z62G6ewNdtMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzOvw_zXNN6TeYgo6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,164</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzOvw_zx6viu8uXn3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,674</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzOvw_maPPAENz9zC_z6ClvyLSUWa4" style="vertical-align: bottom; background-color: White"> <td style="visibility: hidden">Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,296</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,769</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9zC_zbu2qgaRusv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,303</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9zC_zVkzAf5lk2ll" style="vertical-align: bottom; background-color: White"> <td style="visibility: hidden; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,993</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1760000 1732000 463000 363000 3399000 3164000 5674000 5510000 11296000 10769000 6303000 5394000 4993000 5375000 465000 913000 491000 968000 <p id="xdx_80C_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zubQCFkPwJck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9.<span id="xdx_820_zu1VqidQQIF7"> INTANGIBLE ASSETS AND GOODWILL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89B_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_za3I08tpgcxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s intangible assets at June 30, 2020 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B8_z2VDzwB1hsrh" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%">Patents</td><td style="width: 2%"> </td> <td style="width: 12%; text-align: center"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zA9TU1SAfIni" title="Amortization periods (in years)">17</span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zKMaYgD414mf" title="Amortization periods (in years)">19</span> years</td><td style="width: 1%"> </td> <td style="width: 2%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Cost">879</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Accumulated amortization">(80</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Impairment">(363</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Net Carrying value">436</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zdiQpY5l5h53" title="Amortization periods (in years)">20</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" title="Amortization periods description">Indefinite</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost">348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value">348</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_z3KIJpbFozjd" title="Amortization periods (in years)">3</span>-<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zTwSmVTnaeXh" title="Amortization periods (in years)">15</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization">(388</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value">1,131</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zXczuuVmpkKl" title="Amortization periods (in years)">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zsXsqcNujsjl" title="Amortization periods (in years)">3</span>-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zCHFHWhbtaMl" title="Amortization periods (in years)">4</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEr0i04N90d3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_ziaX6ixomDq7" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhtoupANag85" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--IntangibleAssetsNetExcludingsGoodwill_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_ziq1t3s9HQn6" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zmyKqseOZcN9" title="Amortization periods (in years)">25</span> years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(536</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(363</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--IntangibleAssetsNetExcludingsGoodwill_iI_pn3n3_c20200630_zQRfvZqTvnMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">1,960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z3ATcsxTo0f3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three and six months ended June 30, 2020, the Company recorded impairment charges of $<span id="xdx_90C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_c20200101__20200630_zBa9m4fbwQCj">363 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to patent filings associated with the products that the Company was no longer actively selling.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_891_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAfyIXrVZa99" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Amortization expense for intangible assets for the three and six months ended June 30, 2020 and 2019 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zauul4QSFque" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Three Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Three Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGCKsPXDjKeg" style="width: 12%; text-align: right" title="Amortization of intangible assets">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"/><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">102</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zOlQLH10NFn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z6zQ42jgaqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Estimated future amortization expense for the Company’s intangible assets at June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zIVfodeooOt5" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20200630_zxnRM2bOg3Nh" style="text-align: right">2020</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANz1kz_zfHX1hbei9Ob" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">85</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz1kz_zI0yUYOyG3V7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz1kz_z03PP8654hW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz1kz_zdRYSMHFlQL8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz1kz_zKywuRo61TP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANz1kz_zgeiOFnodin7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">891</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz1kz_zyGgovVhnXai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Intangible assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zXEOoPvNJYmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">There have been <span id="xdx_908_eus-gaap--GoodwillAndIntangibleAssetImpairment_pn3n3_do_c20200101__20200630_zCKCxiZ8iPM" title="Changes in carrying value goodwill">no</span> changes in the carrying value of the Company’s goodwill during the three and six months ended June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_za3I08tpgcxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s intangible assets at June 30, 2020 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B8_z2VDzwB1hsrh" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%">Patents</td><td style="width: 2%"> </td> <td style="width: 12%; text-align: center"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zA9TU1SAfIni" title="Amortization periods (in years)">17</span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zKMaYgD414mf" title="Amortization periods (in years)">19</span> years</td><td style="width: 1%"> </td> <td style="width: 2%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Cost">879</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Accumulated amortization">(80</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Impairment">(363</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Net Carrying value">436</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zdiQpY5l5h53" title="Amortization periods (in years)">20</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" title="Amortization periods description">Indefinite</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost">348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value">348</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_z3KIJpbFozjd" title="Amortization periods (in years)">3</span>-<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zTwSmVTnaeXh" title="Amortization periods (in years)">15</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization">(388</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value">1,131</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zXczuuVmpkKl" title="Amortization periods (in years)">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zsXsqcNujsjl" title="Amortization periods (in years)">3</span>-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zCHFHWhbtaMl" title="Amortization periods (in years)">4</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEr0i04N90d3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_ziaX6ixomDq7" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhtoupANag85" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--IntangibleAssetsNetExcludingsGoodwill_iI_pn3n3_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_ziq1t3s9HQn6" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zmyKqseOZcN9" title="Amortization periods (in years)">25</span> years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(536</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(363</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--IntangibleAssetsNetExcludingsGoodwill_iI_pn3n3_c20200630_zQRfvZqTvnMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">1,960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P17Y P19Y 879000 -80000 -363000 436000 P20Y 50000 -6000 44000 Indefinite 348000 348000 P3Y P15Y 1519000 -388000 1131000 P5Y 5000 -5000 P3Y P4Y 50000 -50000 P25Y 8000 -7000 1000 2859000 -536000 -363000 1960000 363000 <p id="xdx_891_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAfyIXrVZa99" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Amortization expense for intangible assets for the three and six months ended June 30, 2020 and 2019 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zauul4QSFque" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Three Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Three Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGCKsPXDjKeg" style="width: 12%; text-align: right" title="Amortization of intangible assets">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"/><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">102</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20200401__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20190401__20190630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 8000 11000 19000 15000 1000 1000 5000 35000 51000 68000 102000 2000 1000 43000 63000 88000 125000 <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z6zQ42jgaqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Estimated future amortization expense for the Company’s intangible assets at June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zIVfodeooOt5" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20200630_zxnRM2bOg3Nh" style="text-align: right">2020</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANz1kz_zfHX1hbei9Ob" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">85</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz1kz_zI0yUYOyG3V7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz1kz_z03PP8654hW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz1kz_zdRYSMHFlQL8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz1kz_zKywuRo61TP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANz1kz_zgeiOFnodin7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">891</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz1kz_zyGgovVhnXai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Intangible assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 85000 166000 166000 166000 138000 891000 1612000 0 <p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zOTLjKxtCx24" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 10. <span id="xdx_825_zFgABYeCuQv2">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcXFgYOrWn0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable and accrued expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_z6UQBy0njpK3" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20200630_zX262PFhaDU3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20191231_zs7htczmTMx9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zcJVIgsR3Qci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_ziWVpmPesNs4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1166"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zgKeRqlryVM" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zdjTwTrjIdgk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for note payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzL96_zweASrUhYp6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zj1SRRi4rwz1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,780</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3_zzFVbkeHBnW7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zcJ4YQecClJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcXFgYOrWn0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable and accrued expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_z6UQBy0njpK3" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20200630_zX262PFhaDU3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20191231_zs7htczmTMx9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zcJVIgsR3Qci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_ziWVpmPesNs4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1166"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zgKeRqlryVM" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zdjTwTrjIdgk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for note payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzL96_zweASrUhYp6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zj1SRRi4rwz1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,780</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3_zzFVbkeHBnW7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5530000 7409000 49000 250000 244000 800000 800000 6580000 8502000 5780000 7702000 800000 800000 <p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zh7yuMQc8lqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 11. <span id="xdx_820_z1wDvKTCcOK3">DEBT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In July 2017, the Company entered into a term loan and security agreement in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zBIhqtGaJCXi">16,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (collectively, “SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five-year term; however, such term could be reduced to four years if certain revenue requirements are not achieved. The SWK Loan is secured by substantially all of the Company’s assets, including its intellectual property rights. The SWK Loan was subsequently amended in May 2019 and again in April 2020 (see below). <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20170730__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zURyCOHhUFLe" title="Debt instrument interest rate description">The SWK Loan bears an interest rate that is equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercent_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zSNuoZeykrSb" title="Debt instrument interest rate">2.00</span>%), plus an applicable margin of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercent_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--BaseRateMember_z9XYCwN5eL58" title="Debt instrument interest rate">10.00</span>% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%. The leverage ratio means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding 12 month period, adding-back (i) actual litigation expenses for the immediately preceding 12 month period, minus (ii) actual litigation expenses for the immediately preceding 3 month period multiplied by 4.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Second Amendment to SWK Loan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On April 1, 2020, the Company and several of its wholly owned subsidiaries entered into a second amendment (the “SWK Amendment”) to the SWK Loan, with SWK. A summary of the material changes contained in the SWK Amendment are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">SWK agreed to make available to the Company, and the Company drew down on, an additional principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20200402__us-gaap--TypeOfArrangementAxis__custom--SWKAmendmentMember_zCPA6ZebU3Q2" title="Debt principal amount">1,000</span>;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Amendment; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The interest payment due May 14, 2020 will be paid in kind by increasing the principal amount of the term loans by an amount equal to the interest accrued as of such date.</p> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Paycheck Protection Program Loan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender, for a loan (the “PPP Loan”) in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_z7C3Ezf7RFj3" title="Debt principal amount">1,967</span> and received cash proceeds of the same amount, pursuant to the Paycheck Protection Program (the “PPP”) under the Federal Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business Administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under the terms of the PPP Loan, interest accrues on the outstanding principal at the rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercent_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_zqHaeuSNWOt9" title="Debt instrument interest rate">1.0</span>% per annum. The term of the PPP Loan is two years, unless sooner required in connection with an event of default under the PPP Loan. To the extent the PPP Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company may apply for and be granted forgiveness for all or part of the PPP Loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the Company during the eight-week period after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments (<span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20200403__20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember" title="Debt instrument interest rate description">it being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs</span>); the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible expenses during the covered eight-week period will qualify for forgiveness. While the Company intends to use proceeds from the PPP Loan for such qualifying expenses, in particular maintaining continuity of its payroll and workforce (including staff critical to the timely production and dispensing of medicines the Company produces), no assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXG9IBaGRJ17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At June 30, 2020, future minimum payments under the Company’s debt agreements were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zuipb3QPGrv1" style="display: none">SUMMARY OF FUTURE MINIMUM PAYMENTS</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200630_zpFcyC1E3849" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzze4_zP708gHpKKqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,439</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzze4_zlx5Cb3VBsbe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,430</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzze4_zxAM1Jm4Mix4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,437</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDzze4_zca5l3zrCrmh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,738</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzze4_zC9t87CfI4dj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,044</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zzUwsIamjn8d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing estimated interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,479</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zcxB9A4koWh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loans payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,565</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zHhwEvVf7EXj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,016</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NotesPayable_iI_pn3n3_zWtEASNN6WF" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,549</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NotesPayableCurrent1_iI_pn3n3_zSnoY4gF4z7l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, net of unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,422</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--LongTermNotesPayable1_iI_pn3n3_zcI4cw4gQG11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loans payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zsdtxZhXI9C5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the three and six months ended June 30, 2020, debt discount amortization related to the SWK Loan was $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20200401__20200630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zMLDIYWclFZ6">83 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20200101__20200630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zQ4E39qHzpV7">243</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively. For the three and six months ended June 30, 2019, debt discount amortization related to the SWK Loan was $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20190401__20190630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zcIjqCl5Rsjh">125 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20190101__20190630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zp236FkkgJU8">263</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 16000000 The SWK Loan bears an interest rate that is equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 2.00%), plus an applicable margin of 10.00% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%. The leverage ratio means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding 12 month period, adding-back (i) actual litigation expenses for the immediately preceding 12 month period, minus (ii) actual litigation expenses for the immediately preceding 3 month period multiplied by 4. 0.0200 0.1000 1000000 1967000 0.010 it being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs <p id="xdx_89C_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXG9IBaGRJ17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At June 30, 2020, future minimum payments under the Company’s debt agreements were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zuipb3QPGrv1" style="display: none">SUMMARY OF FUTURE MINIMUM PAYMENTS</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200630_zpFcyC1E3849" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzze4_zP708gHpKKqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,439</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzze4_zlx5Cb3VBsbe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,430</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzze4_zxAM1Jm4Mix4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,437</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDzze4_zca5l3zrCrmh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,738</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzze4_zC9t87CfI4dj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,044</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zzUwsIamjn8d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing estimated interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,479</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zcxB9A4koWh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loans payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,565</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zHhwEvVf7EXj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,016</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NotesPayable_iI_pn3n3_zWtEASNN6WF" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,549</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NotesPayableCurrent1_iI_pn3n3_zSnoY4gF4z7l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, net of unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,422</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--LongTermNotesPayable1_iI_pn3n3_zcI4cw4gQG11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loans payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2439000 5430000 4437000 9738000 22044000 3479000 18565000 1016000 17549000 -3422000 14127000 83000 243000 125000 263000 <p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_z9j06gcaIFLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 12. <span id="xdx_821_znC9oz0HKv45">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have remaining lease terms between one to four years and contain various clauses for renewal at our option.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An operating lease for <span id="xdx_900_eus-gaap--AreaOfLand_iI_pii_uSqft_c20200630__srt--StatementGeographicalAxis__custom--SanDiegoMember_zCnD6Ifr1xe2" title="Operating lease space">10,200</span> square feet of office space in San Diego, California that expires in <span id="xdx_900_ecustom--LeaseExpirationDateDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--SanDiegoMember_zJVnAZ5XFeve" title="Operating lease expires date">December 2021</span>, with an option to extend the <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--SanDiegoMember" title="Lease term description">term for a five-year period</span>;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An operating lease for <span id="xdx_90B_eus-gaap--AreaOfLand_iI_pii_uSqft_c20200630__srt--StatementGeographicalAxis__custom--IrvineMember_zLHSF7mB6T4b">4,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">square feet of office and lab space in Irvine, California that expires in <span id="xdx_900_ecustom--LeaseExpirationDateDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--IrvineMember_zV8C5ZiKrQR1">December 2020</span></span><span style="font: 10pt Times New Roman, Times, Serif">, with an option to extend the term for up to <span id="xdx_902_eus-gaap--LesseeOperatingLeaseDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--IrvineMember">two five-year periods</span></span><span style="font: 10pt Times New Roman, Times, Serif">. As part of the Company’s restructuring of the Park Compounding, Inc. (“Park”) business, the Company assessed its obligations under this lease. As of the date of this Quarterly Report, management expects the Company to sublease this space and has determined that there is a practical ability to do so, and as a result did not recognize any impairment costs related to this lease and the Company’s right to use the asset;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An operating lease for <span id="xdx_90F_eus-gaap--AreaOfLand_iI_pii_uSqft_c20200630__srt--StatementGeographicalAxis__custom--LedgewoodMember_zHQ1scDXYgmf" title="Operating lease space">25,000</span> square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in <span id="xdx_900_ecustom--LeaseExpirationDateDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--LedgewoodMember_zgI8QLIMO3Ng" title="Operating lease expires date">July 2024</span>, with an option to extend the <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--LedgewoodMember" title="Lease term description">term for two additional five-year periods</span>; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An operating lease for <span id="xdx_909_eus-gaap--AreaOfLand_iI_pii_uSqft_c20200630__srt--StatementGeographicalAxis__custom--NashvilleMember_zgBZF7FeYjbb" title="Operating lease space">5,500</span> square feet of office space in Nashville, Tennessee that expires in <span id="xdx_900_ecustom--LeaseExpirationDateDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--NashvilleMember_zPVo8thKH9Bd" title="Operating lease expires date">December 2024</span>, with an option to extend the term for <span id="xdx_906_eus-gaap--LesseeOperatingLeaseDescription_c20200101__20200630__srt--StatementGeographicalAxis__custom--NashvilleMember" title="Lease term description">two additional five-year periods</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">In March 2020, the Company amended its New Jersey lease for the expansion of an additional <span id="xdx_906_eus-gaap--AreaOfLand_iI_pii_uSqft_c20200331__srt--StatementGeographicalAxis__custom--NewJerseyMember_z9TFabmafbf5">1,400 </span></span><span style="font: 10pt Times New Roman, Times, Serif">square feet of space which is expected to commence in September 2020 and expire in <span id="xdx_905_ecustom--LeaseExpirationDateDescription_c20200331__20200630__srt--StatementGeographicalAxis__custom--NewJerseyMember_zaHW9eP1aZvb">July 2026</span></span><span style="font: 10pt Times New Roman, Times, Serif">. The March 2020 lease is not included below since the new lease term has not commenced as of June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At June 30, 2020, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were <span id="xdx_907_ecustom--OperatingLeaseWeightedAverageIncrementalBorrowingRate_iI_pii_dp_c20200630_zFHngwFuaZp5" title="Weighted average incremental borrowing rate, operating lease">6.32</span>% and <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200630_zghfvM7Rtnv1" title="Weighted average remaining lease term, operating lease">9.85</span> years, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three and six months ended June 30, 2020, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_90C_ecustom--CashPaidInOperatingLeaseLiability_pn3n3_c20200401__20200630_zMpuiStSSqrk" title="Cash paid in operating lease liability">276 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_ecustom--CashPaidInOperatingLeaseLiability_pn3n3_c20200101__20200630_zemUfMC0WYnf" title="Cash paid in operating lease liability">547 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and the Company recorded operating lease expense of $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_pn3n3_c20200401__20200630_zxGcW9xzhAUh" title="Operating lease expense">280</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pn3n3">555</span></span> <span style="font: 10pt Times New Roman, Times, Serif">included in selling, general and administrative expenses, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zVYtTCQZx6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future lease payments under operating leases as of June 30, 2020 were as follows<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BF_z4SiUTqI1xe4" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20200630_zsIGlkh5RxEe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Operating Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzt4I_zDAnnJ4Z4e29" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzt4I_zLjv9EeBEPCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">987</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzt4I_zGmXOXQ4Y8L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzt4I_z06me6EiWTbf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,032</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzt4I_zfPTO9YQG649" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzt4I_ztfE6TTmCyg3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,465</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzt4I_zh05Tq5CBeT7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,083</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z5xg9bKJFU9j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zvMAXMsYVkF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zLUaoa7idDe3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zBeG4qA4ruyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zMAcaQ9lFoca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company also has a lease that is included in its lease accounting but is not considered significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_898_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zMvqmiA4cf5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future lease payments under finance leases as of June 30, 2020 were as follows<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B0_zLoRdJh9mAU3" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200630_z6dys8NfkTX5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Finance Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maFLLPDz8Hr_zmm1Rn3U7SYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDz8Hr_zzdr7gYuTaaa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDz8Hr_zc1DHnwAAst2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDz8Hr_zinlAtbKnSN7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maFLLPDz8Hr_zd7HJY5W4eOb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDz8Hr_z1lq1dyqIRfg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zewCB6OCBzFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zFbmdHhieQn1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_zJuoCuB3aVFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_z7PelHa4Tgh4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zHcigovdx6V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At June 30, 2020, the incremental borrowing rate and the remaining lease term for the finance lease held by the Company were <span id="xdx_901_ecustom--FinanceLeaseWeightedAverageIncrementalBorrowingRate_iI_pii_dp_c20200630_zqW7b3euInD8" title="Weighted average incremental borrowing rate, finance lease">6.36</span>% and <span id="xdx_90B_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200630_zWmawFDK3PMl" title="Weighted average remaining lease term, finance lease">3.58</span> years, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the three and six months ended June 30, 2020, depreciation expense related to the equipment held under the finance lease obligation was $<span id="xdx_904_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_c20200401__20200630_pn3n3">2 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_c20200101__20200630_pn3n3">4</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For each of the three and six months ended June 30, 2020, cash paid and expense recognized for interest expense related to the finance lease obligation was $<span id="xdx_909_eus-gaap--FinanceLeaseInterestExpense_pn3n3_c20200401__20200630_zhDDxxGCMTv7">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_904_eus-gaap--FinanceLeaseInterestExpense_pn3n3_c20200101__20200630_zAgpOhqsv5He">1</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 10200 December 2021 term for a five-year period 4500 December 2020 two five-year periods 25000 July 2024 term for two additional five-year periods 5500 December 2024 two additional five-year periods 1400 July 2026 0.0632 P9Y10M6D 276000 547000 280000 555000 <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zVYtTCQZx6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future lease payments under operating leases as of June 30, 2020 were as follows<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BF_z4SiUTqI1xe4" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20200630_zsIGlkh5RxEe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Operating Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzt4I_zDAnnJ4Z4e29" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzt4I_zLjv9EeBEPCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">987</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzt4I_zGmXOXQ4Y8L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzt4I_z06me6EiWTbf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,032</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzt4I_zfPTO9YQG649" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzt4I_ztfE6TTmCyg3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,465</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzt4I_zh05Tq5CBeT7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,083</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z5xg9bKJFU9j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zvMAXMsYVkF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zLUaoa7idDe3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zBeG4qA4ruyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 556000 987000 1008000 1032000 1035000 4465000 9083000 2406000 6677000 651000 6026000 <p id="xdx_898_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zMvqmiA4cf5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future lease payments under finance leases as of June 30, 2020 were as follows<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B0_zLoRdJh9mAU3" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200630_z6dys8NfkTX5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Finance Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maFLLPDz8Hr_zmm1Rn3U7SYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDz8Hr_zzdr7gYuTaaa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDz8Hr_zc1DHnwAAst2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDz8Hr_zinlAtbKnSN7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maFLLPDz8Hr_zd7HJY5W4eOb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDz8Hr_z1lq1dyqIRfg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zewCB6OCBzFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zFbmdHhieQn1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_zJuoCuB3aVFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_z7PelHa4Tgh4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5000 9000 9000 9000 1000 33000 3000 30000 -8000 22000 0.0636 P3Y6M29D 2000 4000 0 1000 <p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zrW17Riwfmg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 13. <span id="xdx_823_zrN35tlS3hf4">STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In May 2020, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200501__20200531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares">30,000</span> shares of its restricted common stock, with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20200501__20200531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIN3ZijWuk5" title="Fair value of restricted common stock issued">167</span>, as consideration for commission expenses incurred during the year ended December 31, 2019 and the six months ended June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, the Company issued <span id="xdx_909_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_pii_c20200101__20200630_zOmYjuwrT6sh">253 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of its common stock upon the cashless exercise of options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630_zhnIR0mFn50d">750</span> shares of common stock, with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630_zpEKweZUWXgj">3.04 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, net of <span id="xdx_90D_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_pn3n3_c20200101__20200630_z8Wlc5cnkd35">69 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock withheld for payroll tax withholdings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzSvACZzWrh2" title="Shares issued of restricted common stock, shares">91,987</span> shares of its common stock underlying RSUs issued to a director that resigned. The RSUs had previously vested, including <span id="xdx_90F_ecustom--RestrictedStockUnitsVested_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkKwTbSqrtWl" title="Restricted stock units vested">2,429</span> RSUs during the six months ended June 30, 2020, but the issuance and delivery of the shares were deferred until the director resigned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z8evI5FQU23l" title="Shares issued of restricted common stock, shares">17,001</span> shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock Option Plan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan (the “2017 Plan” together with the 2007 Plan, the “Plans”). As of June 30, 2020, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zyRezthP5d3e" title="Maximum number of common stock issuance under the plan">2,000,000</span> shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_znWqWom6Q9F7" title="Shares available for future issuances">414,382</span> shares available for future issuances under the 2017 Plan at June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJzqhBLMK451" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of stock option activity under the Plans for the six months ended June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><span id="xdx_8BC_zk7pFOyeZdW1" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number of shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Remaining Contractual Life</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font: 10pt Times New Roman, Times, Serif">Options outstanding - January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zeD0ONcVQL9d" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">2,656,683</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZh7mQ2cFxcl" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">5.30</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zTauwMXlEEWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options granted"><span style="font: 10pt Times New Roman, Times, Serif">355,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd9r1kAM0X6k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Avg. Exercise Price, Options granted"><span style="font: 10pt Times New Roman, Times, Serif">6.57</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Options exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zkPORcNAT42k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options exercised"><span style="font: 10pt Times New Roman, Times, Serif">(750</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zsIabDX9S85g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Avg. Exercise Price, Options exercised"><span style="font: 10pt Times New Roman, Times, Serif">3.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options cancelled/forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLXRo6fw1oz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options cancelled/forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(8,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPbmi7T5WC01" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited"><span style="font: 10pt Times New Roman, Times, Serif">3.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options outstanding - June 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zH8BtGCg1jv4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Outstanding, Ending balance"><span style="font: 10pt Times New Roman, Times, Serif">3,002,594</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/>$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDlezX4zSiD9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance"><span style="font: 10pt Times New Roman, Times, Serif">5.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z9STACq9xpal" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options outstanding">6.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_znbztvBgdJ6e" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding"><span style="font: 10pt Times New Roman, Times, Serif">3,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options exercisable – June 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3vf8z7hFcR6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1,779,188</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/>$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLCEXGt8tg67" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance"><span style="font: 10pt Times New Roman, Times, Serif">4.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zSyWLm8IdSzb" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iS_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpGQlk5pXHb6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2,749</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options vested and expected to vest – June 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zebMnW3Gqr77" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options vested and expected to vest"><span style="font: 10pt Times New Roman, Times, Serif">2,887,635</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/>$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIg2eCRm49O4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest"><span style="font: 10pt Times New Roman, Times, Serif">5.40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFWTZO8xNHQd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">6.09</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3MwxgvxYJZ4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest"><span style="font: 10pt Times New Roman, Times, Serif">3,107</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A5_z4voI62v6aS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on June 30, 2020, based on the closing price of the Company’s common stock of $<span id="xdx_902_ecustom--ClosingPriceOfCommonStockPricePerShare_iI_pii_c20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zV1dKlDOXJ0f" title="Closing price of common stock price per share">5.21</span> on that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, the Company granted stock options to certain employees and a consultant. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pii_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zgLhwUi3EUN">10 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_ztHCGhTiGaV5">Vesting terms for options granted to employees and consultants during the three months ended June 30, 2020 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On July 31, 2015, the Company granted to its Chief Executive Officer, Mark Baum, an option (the “Baum Performance Option”) to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zXaTg1DKzvfd">600,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company’s common stock at an exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zMG5SzyNdeM9">7.87 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share under the 2007 Plan subject to the satisfaction of certain market-based vesting criteria. The market-based vesting criteria are separated into five tranches and require that the Company achieve and maintain certain average stock price targets ranging from $<span id="xdx_90D_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MinimumMember_pii">9 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share to $<span id="xdx_90A_ecustom--AverageStockPrice_iI_pii_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MaximumMember_zUbsHtgPDBP8">15 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share during the five year period following the grant date. On June 4, 2020, the Company amended the Baum Performance Option, to extend the vesting and contractual term by <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zxfYkDf97UIi">5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years. The Company treated this amendment as a modification to the Baum Performance Option for accounting purposes. The fair value of the modification was $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zGUDKCA0PAo4">1</span></span><span style="font: 10pt Times New Roman, Times, Serif">,876 using a Monte Carlo Simulation with a five year life, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercent_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zrZy2KjtOFbi">70</span></span><span style="font: 10pt Times New Roman, Times, Serif">% volatility and a risk-free interest rate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercent_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zvekg5R2Cuf7">0.40</span></span><span style="font: 10pt Times New Roman, Times, Serif">%. The fair value of the modification will be recognized as stock-based compensation expense over the service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With the exception of the Baum Performance Option, the fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture rate of <span id="xdx_90B_ecustom--ForfeitureFactorPercentage_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zVTswzThG5X8" title="Forfeiture factor, percentage">10</span>%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOrOC4RMfwck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zyuLKGG251va" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZOIMmlfOduj" style="width: 22%; text-align: right" title="Weighted-average fair value of options granted">3.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zstkj7Dwn4c6" style="font: 10pt Times New Roman, Times, Serif">0.5 </span><span style="font: 10pt Times New Roman, Times, Serif">– <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zQkrJMlUrf57">6.11</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmHPbeS1obEd" style="font: 10pt Times New Roman, Times, Serif">66</span><span style="font: 10pt Times New Roman, Times, Serif">% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zSgMCFEuXLbb">71</span></span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z0nZWCgLML81" style="font: 10pt Times New Roman, Times, Serif">0.50</span><span style="font: 10pt Times New Roman, Times, Serif">% </span><span style="font: 10pt Times New Roman, Times, Serif">- <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zuvShddzUXt4">1.64</span></span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_ziuOjas33bG3" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_ztvl5DOshZaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zJSIjJIfkfGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes information about stock options outstanding and exercisable at June 30, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_zFOfCbs6kM5h" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Options Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Options Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Average</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Remaining</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Average</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Average</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Range of</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">Contractual</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise Prices</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Life in Years</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Price</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Price</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: right">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum">2.60</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Number of Options Outstanding">778,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zneYGz5TnWl1" style="width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Weighted Average Exercise Price">2.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Number Exercisable">699,301</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Weighted Average Exercisable Exercise Price">2.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">$<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, minimum">2.76</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9afAX5jfsv1" title="Range of Exercise Prices, maximum">4.66</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number of Options Outstanding">535,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAdVyf1iT5d3" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercise Price">3.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number Exercisable">455,531</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">$<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum">5.49</span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum">6.36</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number of Options Outstanding">437,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2Wp1FQ6E5ql" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">7.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercise Price">6.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number Exercisable">235,710</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, minimum">6.64</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, maximum">8.99</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Number of Options Outstanding">1,246,241</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z1W8OvxmJRh7" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Weighted Average Exercise Price">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Number Exercisable">383,616</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price">8.19</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTg4bBQuj248" style="text-align: right; padding-bottom: 1.5pt" title="Range of Exercise Prices, maximum">$42.80</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">5,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3DXplVQ91Pb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">0.12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">42.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">5,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">42.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630_pii" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20200630_zKJUYWTAFRK" title="Range of Exercise Prices, maximum">42.80</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">3,002,594</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630_zqyqWjQKgIYe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">5.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">1,779,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">4.53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zKBKUBTYxr1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2020, there was approximately $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zJD2baWplX2j">6,383 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of total unrecognized compensation expense related to unvested stock options granted under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zmIk9Z6K7GOh">4.09 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years. The stock-based compensation expense for all stock options was $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pn3n3_c20200401__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zrxbpmRHPw74">271 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zyQnytU8Rmb3">534 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and six months ended June 30, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Restricted Stock Units</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three and six months ended June 30, 2020, the Company’s board of directors were granted <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares">68,024</span></span> RSUs with a fair market value $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued">400</span></span> which vest on a quarterly basis, over one year in equal installments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three and six months ended June 30, 2020, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200401__20200630__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember_pii" title="Shares issued of restricted common stock, shares"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200630__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember_pii" title="Shares issued of restricted common stock, shares">161,000</span></span> RSUs with a fair market value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200401__20200630__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember_pn3n3" title="Fair value of restricted common stock issued"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20200630__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember_pn3n3" title="Fair value of restricted common stock issued">1,025</span></span> were issued to certain employees; the RSUs vest in full on the third anniversary of the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><br/> During the six months ended June 30, 2020, the Company granted <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200630__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsMember_pii">10,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">RSUs to a new member of its board of directors, with a fair market value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsMember_z6sleZKGCojd">39 </span></span><span style="font: 10pt Times New Roman, Times, Serif">which vest on the one-year anniversary of the date granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zsvgndJH7W6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of the Company’s RSU activity and related information for the six months ended June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zAzCsC7cBFoe" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number of RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%">RSUs unvested - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjdaJZBQZ2s3" style="width: 25%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,411,930</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm8ZPK7aoYe1" style="width: 25%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">2.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD86PY7yHgU3" style="text-align: right" title="Number of RSUs granted">239,024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">6.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6owVe4s6EZi" style="text-align: right" title="Number of RSUs vested">(19,430</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">7.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2NQLr2hAZ46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at June 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrz9DGG7sftd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">1,631,524</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5q742DMx4v3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">3.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zeKj4sYFPha3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2020, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20200630__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zrq08iTU9EUi" title="Unrecognized compensation expense related to unvested stock options granted under the plan">1,967</span>, which is expected to be recognized over a weighted-average period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zgoA8PEzwQhe" title="Expense expected to recognize over the weighted-average remaining vesting period">0.5</span> years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three and six months ended June 30, 2020 was $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200401__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation">268</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zX5QCgLaBAib" title="Stock-based compensation">527</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders, underwriters and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQdZNsDMb7xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of warrant activity for the six months ended June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_z8gjyfwaHIec" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number of Shares Subject to Warrants Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9QHgGSCDGok" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zm5Tdk7GV4Sf" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1551">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1553">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - June 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEiTT2H5dmId" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zydHkv87xbPg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - June 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zTLrtdBJxhH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years">4.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zBKaiefrejbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_z6rtX2onJGRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding and exercisable as of June 30, 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_zLvNbMQfjnvb" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Expiration</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">Warrant Series</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Issue Date</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td id="xdx_988_ecustom--WarrantsIssuanceDate_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zDMUJ22UBal8" style="width: 18%; text-align: center" title="Issue Date">5/11/2015</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 17%; text-align: right" title="Warrants Outstanding">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 16%; text-align: right" title="Exercise Price">1.79</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_ecustom--WarrantsAndRightsOutstandingMaturityDates_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zTrj7DXDnTI3" style="width: 17%; text-align: right" title="Expiration Date">5/11/2025</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement warrants</td><td> </td> <td id="xdx_982_ecustom--WarrantsIssuanceDate_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_z6DHpfmzPzu4" style="text-align: center" title="Issue Date">8/16/2016</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsAndRightsOutstandingMaturityDates_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_z5JBfSsZmwih" style="text-align: right" title="Expiration Date">8/16/2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lender warrants</td><td style="padding-bottom: 1.5pt"> </td> <td id="xdx_986_ecustom--WarrantsIssuanceDate_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zviWTCqSNxC8" style="text-align: center; padding-bottom: 1.5pt" title="Issue Date">7/19/2017</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding">615,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">2.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_ecustom--WarrantsAndRightsOutstandingMaturityDates_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zc7O8ASQfaDa" style="padding-bottom: 1.5pt; text-align: right" title="Expiration Date">7/19/2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zOOp90ManKn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Subsidiary Stock-Based Transactions</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Mayfield Pharmaceuticals, Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, Mayfield repurchased <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_zShbyNWOftd3">650,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of its common stock from Elle, for an aggregate purchase price of $<span id="xdx_905_ecustom--AggregatePurchasePrice_pii_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_zMeMMMGp5CSh">1</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 258pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, Mayfield issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zApLI8QsTe1l">475,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of its restricted common stock, with a fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqamk4xwmvxj">11</span></span><span style="font: 10pt Times New Roman, Times, Serif">, that vest upon various performance-based milestones and over a four-year service period to Mayfield’s Chief Executive Officer candidate. During the three and six months ended June 30, 2020, the Company recognized $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pn3n3_c20200401__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember_zOAOGfqzqNB">6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember_zzYdVe9iX266">17</span></span><span style="font: 10pt Times New Roman, Times, Serif">, </span><span style="font: 10pt Times New Roman, Times, Serif">respectively, in stock-based compensation tied to the Mayfield stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 258pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2020, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zSyi0DR5um19" title="Shares issued of restricted common stock, shares">500,000</span> shares of Mayfield’s restricted common stock were forfeited by a consultant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock-Based Compensation Summary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zpZK6NRIxCl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B5_zmvKfazg6jFh" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zx7CV4foKuyh" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">436</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">268</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zYReZtXqklCh" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">872</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190101__20190630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_z3KePsrv3OXa" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">906</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Directors - selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zNqbnu1T6xyk" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Consultants - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zlMFB4pz5v12" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190401__20190630_zz9BgBL2GTK8" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">367</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_zQlch4tQlCh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,161</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,155</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z0F8p6vSWc2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 30000 167000 253 750 3.04 69000 91987 2429 17001 2000000 414382 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJzqhBLMK451" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of stock option activity under the Plans for the six months ended June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><span id="xdx_8BC_zk7pFOyeZdW1" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number of shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Remaining Contractual Life</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font: 10pt Times New Roman, Times, Serif">Options outstanding - January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zeD0ONcVQL9d" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">2,656,683</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZh7mQ2cFxcl" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">5.30</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zTauwMXlEEWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options granted"><span style="font: 10pt Times New Roman, Times, Serif">355,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd9r1kAM0X6k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Avg. Exercise Price, Options granted"><span style="font: 10pt Times New Roman, Times, Serif">6.57</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Options exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zkPORcNAT42k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options exercised"><span style="font: 10pt Times New Roman, Times, Serif">(750</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zsIabDX9S85g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Avg. Exercise Price, Options exercised"><span style="font: 10pt Times New Roman, Times, Serif">3.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options cancelled/forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLXRo6fw1oz8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options cancelled/forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(8,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPbmi7T5WC01" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited"><span style="font: 10pt Times New Roman, Times, Serif">3.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options outstanding - June 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zH8BtGCg1jv4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Outstanding, Ending balance"><span style="font: 10pt Times New Roman, Times, Serif">3,002,594</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/>$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDlezX4zSiD9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance"><span style="font: 10pt Times New Roman, Times, Serif">5.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z9STACq9xpal" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options outstanding">6.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_znbztvBgdJ6e" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding"><span style="font: 10pt Times New Roman, Times, Serif">3,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options exercisable – June 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3vf8z7hFcR6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1,779,188</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/>$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLCEXGt8tg67" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance"><span style="font: 10pt Times New Roman, Times, Serif">4.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zSyWLm8IdSzb" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iS_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpGQlk5pXHb6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2,749</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Options vested and expected to vest – June 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zebMnW3Gqr77" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Options vested and expected to vest"><span style="font: 10pt Times New Roman, Times, Serif">2,887,635</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/>$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIg2eCRm49O4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest"><span style="font: 10pt Times New Roman, Times, Serif">5.40</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFWTZO8xNHQd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">6.09</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3MwxgvxYJZ4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest"><span style="font: 10pt Times New Roman, Times, Serif">3,107</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 2656683 5.30 355500 6.57 750 3.04 8839 3.79 3002594 5.46 P6Y1M20D 3118000 1779188 4.53 P5Y5M23D 2749000 2887635 5.40 P6Y1M2D 3107000 5.21 P10Y Vesting terms for options granted to employees and consultants during the three months ended June 30, 2020 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement. 600000 7.87 9 15 P5Y 1000 0.70 0.0040 0.10 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOrOC4RMfwck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zyuLKGG251va" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZOIMmlfOduj" style="width: 22%; text-align: right" title="Weighted-average fair value of options granted">3.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zstkj7Dwn4c6" style="font: 10pt Times New Roman, Times, Serif">0.5 </span><span style="font: 10pt Times New Roman, Times, Serif">– <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zQkrJMlUrf57">6.11</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmHPbeS1obEd" style="font: 10pt Times New Roman, Times, Serif">66</span><span style="font: 10pt Times New Roman, Times, Serif">% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zSgMCFEuXLbb">71</span></span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z0nZWCgLML81" style="font: 10pt Times New Roman, Times, Serif">0.50</span><span style="font: 10pt Times New Roman, Times, Serif">% </span><span style="font: 10pt Times New Roman, Times, Serif">- <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zuvShddzUXt4">1.64</span></span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20200630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_ziuOjas33bG3" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></span></td><td style="text-align: left"> </td></tr> </table> 3.93 P0Y6M P6Y1M9D 0.66 0.71 0.0050 0.0164 <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zJSIjJIfkfGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes information about stock options outstanding and exercisable at June 30, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_zFOfCbs6kM5h" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Options Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Options Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Average</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Remaining</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Average</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Average</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Range of</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">Contractual</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise Prices</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Life in Years</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Price</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Price</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: right">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum">2.60</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Number of Options Outstanding">778,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zneYGz5TnWl1" style="width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Weighted Average Exercise Price">2.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Number Exercisable">699,301</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 14%; text-align: right" title="Weighted Average Exercisable Exercise Price">2.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">$<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, minimum">2.76</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9afAX5jfsv1" title="Range of Exercise Prices, maximum">4.66</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number of Options Outstanding">535,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAdVyf1iT5d3" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercise Price">3.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number Exercisable">455,531</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">$<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum">5.49</span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum">6.36</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number of Options Outstanding">437,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2Wp1FQ6E5ql" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">7.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercise Price">6.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number Exercisable">235,710</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, minimum">6.64</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, maximum">8.99</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Number of Options Outstanding">1,246,241</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z1W8OvxmJRh7" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Weighted Average Exercise Price">7.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Number Exercisable">383,616</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price">8.19</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTg4bBQuj248" style="text-align: right; padding-bottom: 1.5pt" title="Range of Exercise Prices, maximum">$42.80</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">5,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3DXplVQ91Pb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">0.12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">42.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">5,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">42.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200630_pii" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20200630_zKJUYWTAFRK" title="Range of Exercise Prices, maximum">42.80</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">3,002,594</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200630_zqyqWjQKgIYe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20200630_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">5.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">1,779,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200630_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">4.53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1.47 2.60 778690 P6Y1M24D 2.05 699301 2.08 2.76 4.66 535283 P6Y2M15D 3.98 455531 3.98 5.49 6.36 437350 P7Y4M24D 6.15 235710 6.11 6.64 8.99 1246241 P5Y8M1D 7.85 383616 8.19 42.80 5030 P0Y1M13D 42.80 5030 42.80 1.47 42.80 3002594 P6Y1M20D 5.46 1779188 4.53 6383000 P4Y1M2D 271000 534000 68024 68024 400000 400000 161000 161000 1025000 1025000 10000 39000 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zsvgndJH7W6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of the Company’s RSU activity and related information for the six months ended June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zAzCsC7cBFoe" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number of RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%">RSUs unvested - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjdaJZBQZ2s3" style="width: 25%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,411,930</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm8ZPK7aoYe1" style="width: 25%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">2.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD86PY7yHgU3" style="text-align: right" title="Number of RSUs granted">239,024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">6.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6owVe4s6EZi" style="text-align: right" title="Number of RSUs vested">(19,430</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">7.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2NQLr2hAZ46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at June 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrz9DGG7sftd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">1,631,524</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5q742DMx4v3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">3.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1411930 2.76 239024 6.13 19430 7.72 1631524 3.19 1967000 P0Y6M 268000 527000 <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQdZNsDMb7xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of warrant activity for the six months ended June 30, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_z8gjyfwaHIec" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Number of Shares Subject to Warrants Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Weighted Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9QHgGSCDGok" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zm5Tdk7GV4Sf" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1551">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1553">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - June 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEiTT2H5dmId" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zydHkv87xbPg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - June 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zTLrtdBJxhH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years">4.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 780386 2.12 780386 2.12 P4Y10D <p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_z6rtX2onJGRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding and exercisable as of June 30, 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_zLvNbMQfjnvb" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Expiration</span></td><td style="font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">Warrant Series</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Issue Date</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td id="xdx_988_ecustom--WarrantsIssuanceDate_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zDMUJ22UBal8" style="width: 18%; text-align: center" title="Issue Date">5/11/2015</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 17%; text-align: right" title="Warrants Outstanding">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 16%; text-align: right" title="Exercise Price">1.79</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_ecustom--WarrantsAndRightsOutstandingMaturityDates_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zTrj7DXDnTI3" style="width: 17%; text-align: right" title="Expiration Date">5/11/2025</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement warrants</td><td> </td> <td id="xdx_982_ecustom--WarrantsIssuanceDate_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_z6DHpfmzPzu4" style="text-align: center" title="Issue Date">8/16/2016</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsAndRightsOutstandingMaturityDates_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_z5JBfSsZmwih" style="text-align: right" title="Expiration Date">8/16/2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lender warrants</td><td style="padding-bottom: 1.5pt"> </td> <td id="xdx_986_ecustom--WarrantsIssuanceDate_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zviWTCqSNxC8" style="text-align: center; padding-bottom: 1.5pt" title="Issue Date">7/19/2017</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding">615,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">2.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_ecustom--WarrantsAndRightsOutstandingMaturityDates_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zc7O8ASQfaDa" style="padding-bottom: 1.5pt; text-align: right" title="Expiration Date">7/19/2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2015-05-11 125000 1.79 2025-05-11 2016-08-16 40000 3.75 2021-08-16 2017-07-19 615386 2.08 2024-07-19 780386 2.12 650000 1 475000 11000 6000 17000 500000 <p id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zpZK6NRIxCl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B5_zmvKfazg6jFh" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zx7CV4foKuyh" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">436</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">268</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zYReZtXqklCh" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">872</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190101__20190630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_z3KePsrv3OXa" style="width: 11%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">906</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Directors - selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zNqbnu1T6xyk" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Consultants - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zlMFB4pz5v12" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190630__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190401__20190630_zz9BgBL2GTK8" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">367</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_zQlch4tQlCh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,161</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,155</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 436000 268000 872000 906000 96000 75000 193000 150000 96000 24000 96000 99000 628000 367000 1161000 1155000 <p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zj0VdSGbsu8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 14. <span id="xdx_825_zArOcNLNuMu9">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Novel Drug Solutions et al.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively “NDS”) filed a lawsuit against the Company in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract, leaving only claims related to the scope of the post-termination obligations to be litigated. NDS is seeking unspecified damages, interest, attorney’s fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Product and Professional Liability</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>John Erick et al.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively “Erick”) filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick. In April 2018, Erick filed an amendment to the lawsuit, naming us as a co-defendant. In September 2018, co-defendant Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively “Spectrum”). The cross-complaint seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October 2018. The case is currently in the discovery phase. Erick is seeking unspecified damages, interest, attorney’s fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation, it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General and Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Indemnities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In addition to the indemnification provisions contained in the Company’s governing documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Klarity License Agreement – Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company entered into a license agreement in April 2017 and as amended in April 2018, (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity used to protect and rehabilitate the ocular surface (the “Klarity Product”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" style="font: 10pt Times New Roman, Times, Serif">Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.</span> <span style="font: 10pt Times New Roman, Times, Serif">In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_904_eus-gaap--RoyaltyExpense_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z6oSee3tJK4b">50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">upon execution of the Klarity License Agreement, (ii) a second payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zjt0Qwp7TUu6">50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">following the first $<span id="xdx_905_ecustom--NetSalesRevenue_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zhvXU1dWQdPk">50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in net sales of the Klarity Product; and (iii) a final payment of $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">following the first $<span id="xdx_902_ecustom--NetSalesRevenue_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zwC9hk0Zb0q9">100 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in net sales of the Klarity Product. All of the above referenced milestone payments are payable at the Company’s election in cash or shares of the Company’s restricted common stock. Payments totaling $<span id="xdx_909_ecustom--MilestonePaymentInCash_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--MilestonePaymentInCash_pn3n3_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7Oi3JRLDSR5">55 </span></span><span style="font: 10pt Times New Roman, Times, Serif">were made during the three and six months ended June 30, 2020, respectively. Royalty expense of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">27 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z6KnJqJB3CP7">56 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was incurred during the three and six months ended June 30, 2020, respectively, and is included in accounts payable and is due to Dr. Lindstrom at June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Injectable Asset Purchase Agreement – Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under the terms of the Lindstrom APA, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. </span></span><span style="font: 10pt Times New Roman, Times, Serif">In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">33 </span></span><span style="font: 10pt Times New Roman, Times, Serif">upon execution of the Lindstrom APA. Dr. Lindstrom was paid $<span id="xdx_90F_ecustom--MilestonePaymentInCash_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--MilestonePaymentInCash_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in cash during the three and six months ended June 30, 2020, respectively, and an additional $<span id="xdx_90B_ecustom--MilestonePaymentInCash_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zOAXpyeByXxh">42 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was payable to Dr. Lindstrom at June 30, 2020. The Company incurred royalty expense of $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn3n3_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z8djHHXGKrQk">4 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">42 </span></span><span style="font: 10pt Times New Roman, Times, Serif"> related to the Lindstrom APA during the three and six months ended June 30, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Sales and Marketing Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has entered various sales and marketing agreements with certain organizations, to provide exclusive sales and marketing representation services to Harrow in select geographies in the U.S., in connection with our ophthalmic compounded formulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under the terms of the sales and marketing agreements, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember">the Company is required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts.</span></span> <span style="font: 10pt Times New Roman, Times, Serif">In addition, the Company is required to issue shares of the Company’s restricted common stock to certain organizations if net sales in the assigned territory reach certain future milestone levels by the end of their terms, as applicable. Commission expenses of $<span id="xdx_900_eus-gaap--SalesCommissionsAndFees_pn3n3_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zSEru7SD7ezj">318 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--SalesCommissionsAndFees_pn3n3_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zZAEy3pvKbT1">921 </span></span><span style="font: 10pt Times New Roman, Times, Serif">were incurred under these agreements during the three and six months ended June 30, 2020, respectively, of which $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">83 </span></span><span style="font: 10pt Times New Roman, Times, Serif">were stock-based payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Asset Purchase, License and Related Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. Royalty expenses of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pn3n3_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_z1aGRTXCCrEb">117 </span>and $<span id="xdx_908_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zD89Vw1iDop5">261 </span>and $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pn3n3_c20190401__20190630__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_z5MiwrL3YGy6">274 </span>and $<span id="xdx_903_eus-gaap--RoyaltyExpense_pn3n3_c20190101__20190630__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zmENZGcXc7Sh">465 </span>were incurred under these agreements for the three and six months ended June 30, 2020 and 2019, respectively, and $<span id="xdx_908_eus-gaap--AccountsPayableCurrentAndNoncurrent_c20190630__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_pn3n3">431 </span>and $<span id="xdx_909_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20191231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zrdzeqtYMH7g">274 </span>are included in accounts payable at June 30, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. 50000 50000 50000 50000 100000 0 55000 27000 56000 the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. 33000 0 7000 42000 4000 42000 the Company is required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts. 318000 921000 0 83000 117000 261000 274000 465000 431000 274000 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_ze94L3E1bqY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 15. <span id="xdx_829_z8juI4cVcZi8">SEGMENT INFORMATION AND CONCENTRATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management evaluates performance of the Company based on operating segments. Segment performance for its <span id="xdx_90A_ecustom--NumberOfOperatingSegmentsDescription_c20200101__20200602_zsruqKG72zv" title="Number of operating segments, description">two operating segments</span> is based on segment contribution. The Company’s reportable segments consist of (i) its commercial stage pharmaceutical compounding business (Pharmaceutical Compounding), generally including the operations of the ImprimisRx business; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development, selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like shared expenses.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other select revenues and operating expenses including research and development expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total assets including capital expenditures.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company defines segment net revenues as pharmaceutical compounded drug sales, licenses and other revenue derived from related agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling, general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs, professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which are general in nature and attributable to the segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z4Zu4z9OIZEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and six months ended June 30, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B9_zXM68wsBwaJe" style="display: none">Schedule of Segment Net Revenues, Segment Operating Expenses and Segment Contribution</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical Drug</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zLBuKFPQ2uVh" style="width: 15%; text-align: right" title="Total Revenues">8,060</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zTSP7qDbWt1g" style="width: 17%; text-align: right" title="Total Revenues">           <span style="-sec-ix-hidden: xdx2ixbrl1671"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zU3T0N2AYXD3" style="width: 15%; text-align: right" title="Total Revenues">8,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zEZFPmkbNKI6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zDBoGb3DA1c7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zrzgXlxOYCn6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zJGQDshzJI48" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zMo4Ynsiuvi3" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1683">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTpFni3sERwk" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_znVbMJR53xme" style="text-align: right" title="Selling, general and administrative">4,598</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zQfTmcpXWhY3" style="text-align: right" title="Selling, general and administrative">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zqFL7zUwJoia" style="text-align: right" title="Selling, general and administrative">4,641</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_z4Q5JPJxpEK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">497</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zIiN1zQLvsT8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2go2DfFB6i1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zKK2JOrLmDnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(239</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z9moFN64vls4" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(89</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2pLHro8qVo3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zdDQafC3DwZi" style="text-align: right" title="Operating loss">2,270</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zezoNFDs5nN5" style="text-align: right" title="Operating loss">206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AdjustmentForAmortization_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxGF0hHNLDMb" style="text-align: right" title="Amortization">43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ImpairmentAndDisposalOfLonglivedAssets_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zCGHyH6CrfT1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zOafoOP1eM" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(3,210</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Six Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical Drug</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_z8Fs6h9Ie0k3" style="width: 15%; text-align: right" title="Total Revenues">19,877</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z0T1u50rFZIc" style="width: 17%; text-align: right" title="Total Revenues">          <span style="-sec-ix-hidden: xdx2ixbrl1717"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zGgRWfFvT4Cj" style="width: 15%; text-align: right" title="Total Revenues">19,877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zajofoNWOLO7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zgUq33uKjh98" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1723">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zG3fvJmEBlQ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zgLVM7vSGFJe" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zkRtoPa3I2cb" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1729">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zhAcxkX3zp2l" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zPHIToJqpH0e" style="text-align: right" title="Selling, general and administrative">11,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z4U3zzLdaz92" style="text-align: right" title="Selling, general and administrative">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTzudgg9FsKi" style="text-align: right" title="Selling, general and administrative">11,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zOW9HBbIcRdc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">540</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z9efo2LCCRAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">57</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zm13SaKUQ9Qh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--SegmentContribution_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zPgxRxLUcJla" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,269</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--SegmentContribution_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zJ1vNPdxO5i5" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--SegmentContribution_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1HhgbdR1R02" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zFdlPGhld80h" style="text-align: right" title="Operating loss">3,957</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zAYPWoaFzw15" style="text-align: right" title="Operating loss">555</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AdjustmentForAmortization_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJlqc7dJBg5b" style="text-align: right" title="Amortization">88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zY3tLO9JpXRj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkJxqO5MSoui" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(3,838</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zAC6FoOKCli3" style="width: 15%; text-align: right" title="Total Revenues">13,516</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zKk77HJV4mvk" style="width: 17%; text-align: right" title="Total Revenues">          <span style="-sec-ix-hidden: xdx2ixbrl1763"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJMKQzpE3qZ3" style="width: 15%; text-align: right" title="Total Revenues">13,516</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zXAD88P3eS2l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(5,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zxT1r5QPpyA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1Xh8wI6Qp55" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(5,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zElqqWvLyvW1" style="text-align: right" title="Gross profit">8,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--GrossProfit_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zrQHsudCLYNe" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1775">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z9JjBfNF7SR3" style="text-align: right" title="Gross profit">8,291</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zSDKqFfSeUSg" style="text-align: right" title="Selling, general and administrative">5,804</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zTYHyv8jzt21" style="text-align: right" title="Selling, general and administrative">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcdG0QMB7FHe" style="text-align: right" title="Selling, general and administrative">5,847</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zx9s3Amh6D8d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">533</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zjeLK7iLgvZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zT2dVbMH2Ohc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">660</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SegmentContribution_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zsgarPfN9l6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,954</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--SegmentContribution_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zAQqMFS760N4" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(170</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--SegmentContribution_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zBtBmlxt4UCc" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingIncomeLoss_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxkOeqLw5UJk" style="text-align: right" title="Operating loss">2,342</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNiZWwCc9lg" style="text-align: right" title="Operating loss">150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AdjustmentForAmortization_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zi6aP5ghdMgg" style="text-align: right" title="Amortization">59</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ImpairmentAndDisposalOfLonglivedAssets_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zEfXvsnwixN1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zI48PSmAHyJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(767</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Six Months Ended June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical Drug</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zh6MJEIhqtn7" style="width: 15%; text-align: right" title="Total Revenues">25,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zj8PWf4xrx5f" style="width: 17%; text-align: right" title="Total Revenues">           <span style="-sec-ix-hidden: xdx2ixbrl1809"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcznKc1YQt04" style="width: 15%; text-align: right" title="Total Revenues">25,806</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zM6Dk2laWGFd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(9,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zOjbSCehJ577" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zjYwPBcEULBf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(9,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zUtqsdA5TtOa" style="text-align: right" title="Gross profit">16,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GrossProfit_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zhyCMFfns8sf" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1821">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GrossProfit_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zIPMfTYQK602" style="text-align: right" title="Gross profit">16,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zletvR2Wkmvh" style="text-align: right" title="Selling, general and administrative">11,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zvNrmf9mFVva" style="text-align: right" title="Selling, general and administrative">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxq82q0Sciv9" style="text-align: right" title="Selling, general and administrative">11,605</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zlKFknceg9je" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">658</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zvEKgj0Jk8Q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">263</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxEaWypXgVNb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">921</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--SegmentContribution_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_z5irsKXGhNQ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--SegmentContribution_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zYpmSEmY8ek5" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(349</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--SegmentContribution_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTTVkeIC6X5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zvpLumKRC4r7" style="text-align: right" title="Operating loss">5,061</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4A5y5L9Fhe9" style="text-align: right" title="Operating loss">294</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_ze1jJJ1m2TT4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4uArq4LyoIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(1,323</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A8_zxoZFS5QHlYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues are attributed to the U.S. All long-lived assets at June 30, 2020 and December 31, 2019 are located in the U.S.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company sells its compounded formulations to a large number of customers. No customer accounted for more than <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200401__20200630_zQuIMolfEP5l" title="Percentage of sales derived from large number of customer"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20200630_z5zSinouH0G3" title="Percentage of sales derived from large number of customer"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190401__20190630_zeNTmACOLtS3" title="Maximum percentage of sales derived from large number of customer"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20190630_zxsE2ZhHfeGg" title="Maximum percentage of sales derived from large number of customer">10</span></span></span></span>% of the Company’s total pharmacy sales for the three and six months ended June 30, 2020 and 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><br/> The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200401__20200630__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zMTIYUv0SCI" title="Percentage of sales derived from large number of customer">60</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190401__20190630__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zqp5fUNaj8W4" title="Percentage of sales derived from large number of customer">70</span>% of active pharmaceutical ingredient purchases during the three and six months ended June 30, 2020, respectively, and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20200630__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zoHyXtAgV6eb" title="Percentage of sales derived from large number of customer">69</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20190630__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zrctRCYPnvda" title="Percentage of sales derived from large number of customer">65</span>% during the three and six months ended June 30, 2019, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> two operating segments <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z4Zu4z9OIZEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and six months ended June 30, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B9_zXM68wsBwaJe" style="display: none">Schedule of Segment Net Revenues, Segment Operating Expenses and Segment Contribution</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical Drug</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zLBuKFPQ2uVh" style="width: 15%; text-align: right" title="Total Revenues">8,060</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zTSP7qDbWt1g" style="width: 17%; text-align: right" title="Total Revenues">           <span style="-sec-ix-hidden: xdx2ixbrl1671"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zU3T0N2AYXD3" style="width: 15%; text-align: right" title="Total Revenues">8,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zEZFPmkbNKI6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zDBoGb3DA1c7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zrzgXlxOYCn6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zJGQDshzJI48" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zMo4Ynsiuvi3" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1683">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTpFni3sERwk" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_znVbMJR53xme" style="text-align: right" title="Selling, general and administrative">4,598</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zQfTmcpXWhY3" style="text-align: right" title="Selling, general and administrative">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zqFL7zUwJoia" style="text-align: right" title="Selling, general and administrative">4,641</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_z4Q5JPJxpEK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">497</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zIiN1zQLvsT8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2go2DfFB6i1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zKK2JOrLmDnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(239</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z9moFN64vls4" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(89</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2pLHro8qVo3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zdDQafC3DwZi" style="text-align: right" title="Operating loss">2,270</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zezoNFDs5nN5" style="text-align: right" title="Operating loss">206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AdjustmentForAmortization_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxGF0hHNLDMb" style="text-align: right" title="Amortization">43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ImpairmentAndDisposalOfLonglivedAssets_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zCGHyH6CrfT1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zOafoOP1eM" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(3,210</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Six Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical Drug</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_z8Fs6h9Ie0k3" style="width: 15%; text-align: right" title="Total Revenues">19,877</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z0T1u50rFZIc" style="width: 17%; text-align: right" title="Total Revenues">          <span style="-sec-ix-hidden: xdx2ixbrl1717"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zGgRWfFvT4Cj" style="width: 15%; text-align: right" title="Total Revenues">19,877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zajofoNWOLO7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zgUq33uKjh98" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1723">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zG3fvJmEBlQ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zgLVM7vSGFJe" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zkRtoPa3I2cb" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1729">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zhAcxkX3zp2l" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zPHIToJqpH0e" style="text-align: right" title="Selling, general and administrative">11,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z4U3zzLdaz92" style="text-align: right" title="Selling, general and administrative">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTzudgg9FsKi" style="text-align: right" title="Selling, general and administrative">11,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zOW9HBbIcRdc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">540</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z9efo2LCCRAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">57</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zm13SaKUQ9Qh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--SegmentContribution_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zPgxRxLUcJla" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,269</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--SegmentContribution_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zJ1vNPdxO5i5" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--SegmentContribution_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1HhgbdR1R02" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zFdlPGhld80h" style="text-align: right" title="Operating loss">3,957</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zAYPWoaFzw15" style="text-align: right" title="Operating loss">555</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AdjustmentForAmortization_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJlqc7dJBg5b" style="text-align: right" title="Amortization">88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zY3tLO9JpXRj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkJxqO5MSoui" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(3,838</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zAC6FoOKCli3" style="width: 15%; text-align: right" title="Total Revenues">13,516</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zKk77HJV4mvk" style="width: 17%; text-align: right" title="Total Revenues">          <span style="-sec-ix-hidden: xdx2ixbrl1763"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJMKQzpE3qZ3" style="width: 15%; text-align: right" title="Total Revenues">13,516</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zXAD88P3eS2l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(5,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zxT1r5QPpyA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1Xh8wI6Qp55" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(5,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zElqqWvLyvW1" style="text-align: right" title="Gross profit">8,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--GrossProfit_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zrQHsudCLYNe" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1775">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z9JjBfNF7SR3" style="text-align: right" title="Gross profit">8,291</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zSDKqFfSeUSg" style="text-align: right" title="Selling, general and administrative">5,804</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zTYHyv8jzt21" style="text-align: right" title="Selling, general and administrative">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcdG0QMB7FHe" style="text-align: right" title="Selling, general and administrative">5,847</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zx9s3Amh6D8d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">533</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zjeLK7iLgvZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zT2dVbMH2Ohc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">660</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SegmentContribution_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zsgarPfN9l6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,954</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--SegmentContribution_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zAQqMFS760N4" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(170</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--SegmentContribution_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zBtBmlxt4UCc" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingIncomeLoss_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxkOeqLw5UJk" style="text-align: right" title="Operating loss">2,342</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNiZWwCc9lg" style="text-align: right" title="Operating loss">150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AdjustmentForAmortization_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zi6aP5ghdMgg" style="text-align: right" title="Amortization">59</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ImpairmentAndDisposalOfLonglivedAssets_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zEfXvsnwixN1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_pn3n3_c20190401__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zI48PSmAHyJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(767</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Six Months Ended June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Pharmaceutical Drug</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Development</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zh6MJEIhqtn7" style="width: 15%; text-align: right" title="Total Revenues">25,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zj8PWf4xrx5f" style="width: 17%; text-align: right" title="Total Revenues">           <span style="-sec-ix-hidden: xdx2ixbrl1809"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcznKc1YQt04" style="width: 15%; text-align: right" title="Total Revenues">25,806</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zM6Dk2laWGFd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(9,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zOjbSCehJ577" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zjYwPBcEULBf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(9,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zUtqsdA5TtOa" style="text-align: right" title="Gross profit">16,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GrossProfit_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zhyCMFfns8sf" style="text-align: right" title="Gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1821">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GrossProfit_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zIPMfTYQK602" style="text-align: right" title="Gross profit">16,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zletvR2Wkmvh" style="text-align: right" title="Selling, general and administrative">11,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zvNrmf9mFVva" style="text-align: right" title="Selling, general and administrative">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxq82q0Sciv9" style="text-align: right" title="Selling, general and administrative">11,605</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zlKFknceg9je" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">658</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zvEKgj0Jk8Q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">263</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxEaWypXgVNb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">921</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--SegmentContribution_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_z5irsKXGhNQ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--SegmentContribution_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zYpmSEmY8ek5" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(349</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--SegmentContribution_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTTVkeIC6X5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zvpLumKRC4r7" style="text-align: right" title="Operating loss">5,061</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4A5y5L9Fhe9" style="text-align: right" title="Operating loss">294</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_ze1jJJ1m2TT4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_pn3n3_c20190101__20190630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4uArq4LyoIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating loss">(1,323</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 8060000 8060000 3204000 3204000 4856000 4856000 4598000 43000 4641000 497000 46000 543000 -239000 -89000 -328000 2270000 206000 43000 363000 -3210000 19877000 19877000 6830000 6830000 13047000 13047000 11238000 87000 11325000 540000 57000 597000 1269000 -144000 1125000 3957000 555000 88000 363000 -3838000 13516000 13516000 5225000 5225000 8291000 8291000 5804000 43000 5847000 533000 127000 660000 1954000 -170000 1784000 2342000 150000 59000 -767000 25806000 25806000 9123000 9123000 16683000 16683000 11519000 86000 11605000 658000 263000 921000 4506000 -349000 4157000 5061000 294000 125000 -1323000 0.10 0.10 0.10 0.10 0.60 0.70 0.69 0.65 <p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zoHrjoWI4ek4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 16. <span id="xdx_824_zARSUn2dgL6g">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has performed an evaluation of events occurring subsequent to June 30, 2020 through the filing date of this Quarterly Report. Based on its evaluation, no events other than those described below need to be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In July 2020, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8u0P8t3Cexf">500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of its common stock upon the exercise of options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200701__20200731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpnfpVhJbzNc">500</span> shares of common stock, with an exercise price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20200731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zK6SwJRD9t1j">3.20 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, and received net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20200701__20200731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNJuWMoTwgl2">2</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Eyepoint Commercial Alliance Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On August 1, 2020, the Company, through its wholly-owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU^® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the United States.</span> <span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint will pay the Company a fee calculated based on the quarterly sales of DEXCYU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the <span style="background-color: white">Dexycu Agreement</span>, the Company shall use commercially reasonable efforts to promote and market DEXCYU in the U.S.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Subject to early termination, the <span style="background-color: white">Dexycu Agreement</span> expires on <span id="xdx_901_ecustom--AgreeementExpirationDescription_c20200801__20200802__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCgnATRqRhsd" title="Agreement expiration, description">August 1, 2025</span>, subject to specified notice periods and specified limitations, either party may terminate the <span style="background-color: white">Dexycu Agreement</span> in the event of (i) uncured material breach by the other party or (ii) if DEXCYU ceases to have “pass-through” payment status. In addition, subject to certain limitations, the Company may terminate the <span style="background-color: white">Dexycu Agreement</span> (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change of control. Eyepoint may terminate the <span style="background-color: white">Dexycu Agreement</span>, subject to specified notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods.</span></p> 500 500 3.20 2000 August 1, 2025